Research outputs
2023
Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature
Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Grañana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug–Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS Journal of Acquired Immune Deficiency Syndromes, 92(2), 97-105. doi:10.1097/qai.0000000000003122
2022
Recommendations for the Management of Drug–Drug Interactions Between the <scp>COVID</scp>‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Recommendations for the Management of Drug–Drug Interactions Between the <scp>COVID</scp>‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology & Therapeutics, 112(6), 1191-1200. doi:10.1002/cpt.2646
Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions. Annals of Internal Medicine, 175(5), 744-746. doi:10.7326/m22-0281
Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
Jacobs, T. G., Marzolini, C., Back, D. J., & Burger, D. M. (2022). Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV. Journal of Antimicrobial Chemotherapy, 77(3), 568-573. doi:10.1093/jac/dkab412
Fluvoxamine for the treatment of COVID-19
Marzolini, C., Marra, F., Boyle, A., Khoo, S., & Back, D. J. (2022). Fluvoxamine for the treatment of COVID-19. The Lancet Global Health, 10(3), e331. doi:10.1016/s2214-109x(21)00592-1
2021
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy
Nhean, S., Tseng, A., & Back, D. (2021). The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. Current Opinion in HIV and AIDS, 16(6), 292-302. doi:10.1097/coh.0000000000000701
Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Hodge, D., Back, D. J., Gibbons, S., Khoo, S. H., & Marzolini, C. (2021). Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics, 60(7), 835-853. doi:10.1007/s40262-021-01005-1
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development
Boffito, M., Back, D. J., Flexner, C., Sjö, P., Blaschke, T. F., Horby, P. W., . . . Owen, A. (2021). Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development. Clinical Pharmacology & Therapeutics, 110(1), 64-68. doi:10.1002/cpt.2099
Prescribing in COVID‐19 patients: Should we take into account inflammation?
Marzolini, C., Battegay, M., Sendi, P., & Back, D. J. (2021). Prescribing in COVID‐19 patients: Should we take into account inflammation?. British Journal of Clinical Pharmacology, 87(3), 719-721. doi:10.1111/bcp.14524
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
Marra, F., Smolders, E. J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A. J., . . . Back, D. (2021). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs in R&D, 21(1), 9-27. doi:10.1007/s40268-020-00333-0
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions
Back, D., Marzolini, C., Hodge, D., Marra, F., Boyle, A., Gibbons, S., . . . Khoo, S. (2021). COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(1), 212-213. doi:10.1111/bcp.14358
2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. Journal of Antimicrobial Chemotherapy, 75(12), 3417-3424. doi:10.1093/jac/dkaa340
Safety perspectives on presently considered drugs for the treatment of COVID‐19
Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku‐Betts, C., Alfirevic, A., Back, D., . . . Chadwick, A. E. (2020). Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology. doi:10.1111/bph.15204
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Stader, F., Khoo, S., Stoeckle, M., Back, D., Hirsch, H. H., Battegay, M., & Marzolini, C. (2020). Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. Journal of Antimicrobial Chemotherapy, 75(10), 3084-3086. doi:10.1093/jac/dkaa253
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics
Siccardi, M., Schapiro, J., Di Perri, G., & Back, D. J. (2020). The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. Journal of Antimicrobial Chemotherapy, 75(9), 2381-2383. doi:10.1093/jac/dkaa272
Safety perspectives on presently considered drugs for the treatment of COVID-19
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909
Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
Schulte, B., Wübbolding, M., Marra, F., Port, K., Manns, M. P., Back, D., . . . Maasoumy, B. (2020). Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infectious Diseases, 7(2). doi:10.1093/ofid/ofaa040
The challenge of HIV treatment in an era of polypharmacy
Back, D., & Marzolini, C. (2020). The challenge of HIV treatment in an era of polypharmacy. Journal of the International AIDS Society, 23(2). doi:10.1002/jia2.25449
Drug–drug interactions with direct‐acting antivirals: when do we need to care?
Marra, F., & Back, D. (2020). Drug–drug interactions with direct‐acting antivirals: when do we need to care?. In Unknown Book (pp. 86-93). Wiley. doi:10.1002/9781119533481.ch15
2019
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
Smolders, E. J., Jansen, A. M. E., ter Horst, P. G. J., Rockstroh, J., Back, D. J., & Burger, D. M. (2019). Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clinical Pharmacokinetics, 58(10), 1237-1263. doi:10.1007/s40262-019-00774-0
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV
Cranston, R. D., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . McGowan, I. (2019). A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS Research and Human Retroviruses, 35(9), 794-804. doi:10.1089/aid.2018.0265
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
Back, D., Belperio, P., Bondin, M., Negro, F., Talal, A. H., Park, C., . . . Marra, F. (2019). Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. Journal of Viral Hepatitis, 26(8), 951-960. doi:10.1111/jvh.13110
Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. The Journal of Infectious Diseases, 219(11), 1735-1742. doi:10.1093/infdis/jiy726
Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries
Ferenci, P., Bourgeois, S., Buggisch, P., Norris, S., Curescu, M., Larrey, D., . . . Flisiak, R. (2019). Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries. Journal of Viral Hepatitis, 26(6), 685-696. doi:10.1111/jvh.13080
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring
van Seyen, M., Smolders, E. J., van Wijngaarden, P., Drenth, J. P. H., Wouthuyzen-Bakker, M., de Knegt, R. J., . . . Burger, D. M. (2019). Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. Journal of Hepatology, 70(3), 552-554. doi:10.1016/j.jhep.2018.10.010
Antiretroviral drug-drug interactions in an era of polypharmacy
Back, D. (2019). Antiretroviral drug-drug interactions in an era of polypharmacy. Germs, 9(3), 123-124. doi:10.18683/germs.2019.1166.
2018
Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.
Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
Marra, F., Höner zu Siederdissen, C., Khoo, S., Back, D., Schlag, M., Ouwerkerk‐Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. British Journal of Clinical Pharmacology, 84(5), 961-971. doi:10.1111/bcp.13519
Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma
Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. Journal of Chromatography B, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023
Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.
Pushpakom, S. P., Adaikalakoteswari, A., Owen, A., Back, D. J., Tripathi, G., Kumar, S., . . . Pirmohamed, M. (2018). Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.. Diabetes & vascular disease research, 15(3), 233-242. doi:10.1177/1479164118757924
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
Kidney Diseases Associated with Human Immunodeficiency Virus Infection (2018). New England Journal of Medicine, 378(17), 1654-1656. doi:10.1056/nejmc1800396
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-x
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Jackson, A., Else, L., Higgs, C., Karolia, Z., Khoo, S., Back, D., . . . Boffito, M. (2018). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. HIV Clinical Trials, 19(1), 31-37. doi:10.1080/15284336.2017.1408928
2017
Aging in HIV-Infected Subjects: A New Scenario and a New View.
Negredo, E., Back, D., Blanco, J. -R., Blanco, J., Erlandson, K. M., Garolera, M., . . . Clotet, B. (2017). Aging in HIV-Infected Subjects: A New Scenario and a New View.. BioMed research international, 2017, 5897298. doi:10.1155/2017/5897298
A Call for a Consortium for Optimal Management of Drug–Drug Interactions in Patient Care
Burger, D. M., Smolders, E. J., Schapiro, J., Drenth, J. P. H., & Back, D. J. (2017). A Call for a Consortium for Optimal Management of Drug–Drug Interactions in Patient Care. Clinical Pharmacology & Therapeutics, 102(3), 391-394. doi:10.1002/cpt.648
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika‐Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. Clinical Pharmacology & Therapeutics, 102(3), 529-536. doi:10.1002/cpt.667
Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., & Siccardi, M. (2017). Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clinical Pharmacokinetics, 56(4), 409-420. doi:10.1007/s40262-016-0447-7
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
Seden, K., Gibbons, S., Marzolini, C., Schapiro, J. M., Burger, D. M., Back, D. J., & Khoo, S. H. (2017). Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLOS ONE, 12(3), e0173509. doi:10.1371/journal.pone.0173509
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485
2-Drug regimens in HIV treatment: pharmacological considerations
Back, D. (2017). 2-Drug regimens in HIV treatment: pharmacological considerations. Germs, 7(3), 113-114. doi:10.18683/germs.2017.1115
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study. Therapeutic Drug Monitoring, 39(6), 654-658. doi:10.1097/ftd.0000000000000448
2016
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection
Degasperi, E., Caprioli, F., El Sherif, O., Back, D., Colombo, M., & Aghemo, A. (2016). Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Review of Gastroenterology & Hepatology, 10(12), 1373-1383. doi:10.1080/17474124.2016.1246181
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., . . . Cranston, R. D. (2016). Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. The Lancet HIV, 3(12), e569-e578. doi:10.1016/s2352-3018(16)30113-8
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes, 73(3), 252-257. doi:10.1097/qai.0000000000001108
Long-acting injectable formulations for children and adolescents using PBPK modelling
Rajoli, R. K. R., Back, D., Rannard, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Long-acting injectable formulations for children and adolescents using PBPK modelling. Swansea.
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
Nightingale, S., Chau, T. T. H., Fisher, M., Nelson, M., Winston, A., Else, L., . . . Grp, P. -V. S. (2016). Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 60(8), 4511-4518. doi:10.1128/AAC.00280-16
Pregnancy affects nevirapine pharmacokinetics
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics. Pharmacogenetics and Genomics, 26(8), 381-389. doi:10.1097/fpc.0000000000000227
The development and application of a novel LC–MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma
Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC–MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. Journal of Chromatography B, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040
Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications
Marzolini, C., Gibbons, S., Khoo, S., & Back, D. (2016). Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. Journal of Antimicrobial Chemotherapy, 71(7), 1755-1758. doi:10.1093/jac/dkw032
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. Clinical Pharmacokinetics, 55(7), 861-873. doi:10.1007/s40262-015-0360-5
Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue
Dezzutti, C. S., Else, L. J., Yandura, S. E., Shetler, C., Russo, J., Back, D. J., & McGowan, I. (2016). Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. Antimicrobial Agents and Chemotherapy, 60(5), 2765-2770. doi:10.1128/aac.00167-16
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. Journal of Antimicrobial Chemotherapy, 71(4), 1031-1036. doi:10.1093/jac/dkv425
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. Journal of Antimicrobial Chemotherapy, 71(4), 1041-1045. doi:10.1093/jac/dkv439
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
Penrose, K. J., Parikh, U. M., Hamanishi, K. A., Else, L., Back, D., Boffito, M., . . . Mellors, J. W. (2016). Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). Journal of Infectious Diseases, 213(6), 1013-1017. doi:10.1093/infdis/jiv528
Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
Höner zu Siederdissen, C., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., . . . Wedemeyer, H. (2016). Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clinical Infectious Diseases, 62(5), 561-567. doi:10.1093/cid/civ973
Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports
Fox, J., Brady, M., Alexander, H., Davies, O., Robinson, N., Pace, M., . . . Frater, J. (2016). Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. Infectious Diseases and Therapy, 5(1), 65-71. doi:10.1007/s40121-015-0102-x
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2016). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. Poster session presented at the meeting of Conference on Retroviral and Opportunistic Infections. Boston, MA, USA.
Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (2016). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.
Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro
Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.
Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005–2009
Savage, E. J., Lowndes, C. M., Sullivan, A. K., Back, D. J., Else, L. J., Murphy, G., & Gill, O. N. (2016). Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005–2009. AIDS, 30(1), 145-149. doi:10.1097/qad.0000000000000868
2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV
Rajoli, R. K. R., Back, D. J., Rannard, S., Freel Meyers, C. L., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Clinical Pharmacokinetics, 54(6), 639-650. doi:10.1007/s40262-014-0227-1
Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda
Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. Journal of Antimicrobial Chemotherapy, dkv259. doi:10.1093/jac/dkv259
Reply to “Debilitating fatigue as a treatment indication in chronic hepatitis C”
Pawlotsky, J. -M., Aghemo, A., Back, D., Dusheiko, G., Forns, X., Puoti, M., & Sarrazin, C. (2015). Reply to “Debilitating fatigue as a treatment indication in chronic hepatitis C”. Journal of Hepatology, 63(6), 1535-1536. doi:10.1016/j.jhep.2015.09.004
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/
Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned
Back, D. J., & Burger, D. M. (2015). Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned. Gastroenterology, 149(6), 1315-1317. doi:10.1053/j.gastro.2015.09.031
Twenty years of boosting antiretroviral agents
Boffito, M., Back, D., & Gatell, J. M. (2015). Twenty years of boosting antiretroviral agents. AIDS, 29(17), 2229-2233. doi:10.1097/qad.0000000000000800
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers
Coll, J., Moltó, J., Boix, J., Gómez-Mora, E., Else, L., García, E., . . . Cabrera, C. (2015). Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. AIDS, 29(16), 2149-2154. doi:10.1097/qad.0000000000000769
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrobial Agents and Chemotherapy, 59(10), 6080-6086. doi:10.1128/aac.01441-15
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. Journal of Antimicrobial Chemotherapy, 70(10), 2816-2822. doi:10.1093/jac/dkv174
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156
Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person
El-Sherif, O., & Back, D. (2015). Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person. Current HIV/AIDS Reports, 12(3), 336-343. doi:10.1007/s11904-015-0277-5
Increasing use of ‘party drugs’ in people living with HIV on antiretrovirals
Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of ‘party drugs’ in people living with HIV on antiretrovirals. AIDS, 29(13), 1585-1592. doi:10.1097/qad.0000000000000786
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
Scarsi, K. K., Darin, K. M., Nakalema, S., Back, D. J., Byakika-Kibwika, P., Else, L. J., . . . Lamorde, M. (2016). Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Clinical Infectious Diseases, 62(6), 675-682. doi:10.1093/cid/civ1001
EASL Recommendations on Treatment of Hepatitis C 2015
EASL Recommendations on Treatment of Hepatitis C 2015 (2015). Journal of Hepatology, 63(1), 199-236. doi:10.1016/j.jhep.2015.03.025
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography–Mass Spectrometry
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography–Mass Spectrometry. Therapeutic Drug Monitoring, 37(2), 220-228. doi:10.1097/ftd.0000000000000127
Pharmacogenetics of pregnancy‐induced changes in efavirenz pharmacokinetics
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of pregnancy‐induced changes in efavirenz pharmacokinetics. Clinical Pharmacology & Therapeutics, 97(3), 298-306. doi:10.1002/cpt.43
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. Journal of Antimicrobial Chemotherapy, 70(2), 555-561. doi:10.1093/jac/dku420
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. Journal of Antimicrobial Chemotherapy, 70(2), 550-554. doi:10.1093/jac/dku376
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clinical Trials, 16(1), 39-42. doi:10.1179/1528433614z.0000000006
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults
Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.
Switching Safely: Pharmacokinetics, Efficacy and Safety of Switching Efavirenz to Maraviroc Twice Daily in Patients on Suppressive Antiretroviral Therapy
Waters, L., Jackson, A., Else, L., Rockwood, N., Newell, S., Back, D., . . . Boffito, M. (2015). Switching Safely: Pharmacokinetics, Efficacy and Safety of Switching Efavirenz to Maraviroc Twice Daily in Patients on Suppressive Antiretroviral Therapy. Antiviral Therapy, 20(2), 157-163. doi:10.3851/imp2817
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. Clinical Pharmacokinetics, 54(1), 107-116. doi:10.1007/s40262-014-0184-8
2014
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. Journal of Antimicrobial Chemotherapy, 70(6), 1812-1815. doi:10.1093/jac/dkv035
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant
Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach. Journal of the International AIDS Society, 17(4S3). doi:10.7448/ias.17.4.19586
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy
Else, L., Jackson, V., Brennan, M., Back, D., Khoo, S., Coulter‐Smith, S., & Lambert, J. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV Medicine, 15(10), 604-610. doi:10.1111/hiv.12164
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression
Di Yacovo, M. S., Moltó, J., Ferrer, E., Curran, A., Else, L., Gisslén, M., . . . Podzamczer, D. (2015). Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Journal of Antimicrobial Chemotherapy, 70(5), 1513-1516. doi:10.1093/jac/dku558
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
Else, L., Back, D., Khoo, S. H., & Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.. The Journal of Antimicrobial Chemotherapy, 70(5), 1482-1486. doi:10.1093/jac/dku575
No pharmacokinetic interaction between raltegravir and amlodipine
Singh, G. J., Jackson, A., D’Avolio, A., Else, L., De Nicolò, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine. AIDS, 28(13), 1993-1995. doi:10.1097/qad.0000000000000356
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy
Mora-Peris, B., Watson, V., Vera, J. H., Weston, R., Waldman, A. D., Kaye, S., . . . Winston, A. (2014). Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 69(6), 1642-1647. doi:10.1093/jac/dku018
Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives
Vandekerckhove, L. P. R., Christ, F., Debyser, Z., Owen, A., Back, D., Voet, A., . . . Vogelaers, D. (2014). Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. In Antiviral Research (pp. 71-96). ASM Press. doi:10.1128/9781555815493.ch5
Abacavir forms novel cross-linking abacavir protein adducts in patients
Meng, X., Lawrenson, A. S., Berry, N. G., Maggs, J. L., French, N. S., Back, D. J., . . . Park, B. K. (2014). Abacavir forms novel cross-linking abacavir protein adducts in patients. Chemical Research in Toxicology, 27(04), 524-535. doi:10.1021/tx400406p
A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
Jackson, A. G. A., Else, L. J., Mesquita, P. M. M., Egan, D., Back, D. J., Karolia, Z., . . . Boffito, M. (2014). A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. Clinical Pharmacology & Therapeutics, 96(3), 314-323. doi:10.1038/clpt.2014.118
Antiretroviral drugs for prevention of mother-to-child transmission
Lamorde, M., Schapiro, J. M., Burger, D., & Back, D. J. (2014). Antiretroviral drugs for prevention of mother-to-child transmission. AIDS, 28(17), 2551-2563. doi:10.1097/qad.0000000000000439
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenetics and Genomics, 24(9), 459-463. doi:10.1097/fpc.0000000000000073
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers
Jackson, A., D'Avolio, A., Moyle, G., Bonora, S., Di Perri, G., Else, L., . . . Boffito, M. (2014). Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. Journal of Antimicrobial Chemotherapy, 69(7), 1911-1915. doi:10.1093/jac/dku060
Quantification of Rilpivirine in Human Plasma, Cervicovaginal Fluid, Rectal Fluid and Genital/Rectal Mucosal Tissues Using Liquid Chromatography–Tandem Mass Spectrometry
Else, L. J., Tjia, J., Jackson, A., Penchala, S. D., Egan, D., Boffito, M., . . . Back, D. J. (2014). Quantification of Rilpivirine in Human Plasma, Cervicovaginal Fluid, Rectal Fluid and Genital/Rectal Mucosal Tissues Using Liquid Chromatography–Tandem Mass Spectrometry. Bioanalysis, 6(14), 1907-1921. doi:10.4155/bio.14.59
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?
Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. J Int AIDS Soc, 17(4 Supp), 19583.
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.
2013
Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine
Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013). Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. Antimicrobial Agents and Chemotherapy, 57(12), 6366-6369. doi:10.1128/aac.01124-13
Article Commentary: Drug–Drug Interactions in HIV Therapy: Is it All Clear?
Burger, D., & Back, D. (2013). Article Commentary: Drug–Drug Interactions in HIV Therapy: Is it All Clear?. Antiviral Therapy, 18(5), 649-650. doi:10.3851/imp2688
Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation. Journal of Antimicrobial Chemotherapy, 68(11), 2545-2549. doi:10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. Antimicrobial Agents and Chemotherapy, 57(11), 5612-5618. doi:10.1128/aac.01421-13
The importance of drug–drug interactions in the DAA era
Back, D., & Else, L. (2013). The importance of drug–drug interactions in the DAA era. Digestive and Liver Disease, 45, S343-S348. doi:10.1016/j.dld.2013.07.008
Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics
Moyle, G., Else, L., Jackson, A., Back, D., Yapa, M. H., Seymour, N., . . . Boffito, M. (2013). Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 57(8), 3640-3644. doi:10.1128/aac.00357-13
Validation of an electrospray ionisation LC–MS/MS method for quantitative analysis of telaprevir and its R-diastereomer
Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC–MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. Journal of Chromatography B, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013
Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study
Santos, J. R., Muñoz-Moreno, J. A., Moltó, J., Prats, A., Curran, A., Domingo, P., . . . Clotet, B. (2013). Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study. PLoS ONE, 8(7), e70201. doi:10.1371/journal.pone.0070201
Predicting intestinal absorption of raltegravir using a population-based ADME simulation
Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. Journal of Antimicrobial Chemotherapy, 68(7), 1627-1634. doi:10.1093/jac/dkt084
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 52(7), 583-592. doi:10.1007/s40262-013-0056-7
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring
Winston, A., Jose, S., Gibbons, S., Back, D., Stohr, W., Post, F., . . . Sabin, C. (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. Journal of Antimicrobial Chemotherapy. doi:10.1093/jac/dkt029
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects
Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. Journal of Antimicrobial Chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006
Detection of Drug Bioactivation in Vivo: Mechanism of Nevirapine–Albumin Conjugate Formation in Patients
Meng, X., Howarth, A., Earnshaw, C. J., Jenkins, R. E., French, N. S., Back, D. J., . . . Park, B. K. (2013). Detection of Drug Bioactivation in Vivo: Mechanism of Nevirapine–Albumin Conjugate Formation in Patients. Chemical Research in Toxicology, 26(4), 575-583. doi:10.1021/tx4000107
Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions
Burger, D., Back, D., Buggisch, P., Buti, M., Craxí, A., Foster, G., . . . Zeuzem, S. (2013). Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions. Journal of Hepatology, 58(4), 792-800. doi:10.1016/j.jhep.2012.10.027
Rilpivirine concentrations in seminal plasma in HIV infected patients
Watson, V., Mora-Peris, B., Tjia, J., Vera, J. H., Weston, R., Khoo, S., . . . Winston, A. (2013). Rilpivirine concentrations in seminal plasma in HIV infected patients. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment
Lamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., . . . Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS, 27(6), 961-965. doi:10.1097/qad.0b013e32835cae3b
Drug–drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases
Seden, K., Khoo, S., Back, D., Prevatt, N., Lamorde, M., Byakika-Kibwika, P., . . . Merry, C. (2013). Drug–drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases. AIDS, 27(5), 675-686. doi:10.1097/qad.0b013e32835ca9b4
Non-disclosure of HIV status in UK sexual health clinics—a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey
Sullivan, A. K., Savage, E. J., Lowndes, C. M., Paul, G., Murphy, G., Carne, S., . . . Gill, O. N. (2013). Non-disclosure of HIV status in UK sexual health clinics—a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey. Sexually Transmitted Infections, 89(2), 120-121. doi:10.1136/sextrans-2012-050801
Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation
Jackson, A., Moyle, G., Watson, V., Tjia, J., Ammara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation. JAIDS Journal of Acquired Immune Deficiency Syndromes, 62(3), 275-281. doi:10.1097/qai.0b013e3182829bd0
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention
Jackson, A., Moyle, G., Watson, V., Tjia, J., Amara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62(3), 275-281. doi:10.1097/QAI.0b013e3182829bd0
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting
Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2013). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. Journal of Antimicrobial Chemotherapy, 68(1), 1-3. doi:10.1093/jac/dks346
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
RXRγ gene variants are associated with HIV lipodystrophy
Pushpakom, S. P., Owen, A., Back, D. J., & Pirmohamed, M. (2013). RXRγ gene variants are associated with HIV lipodystrophy. Pharmacogenetics and Genomics, 23(8), 438-441. doi:10.1097/fpc.0b013e328362cfc6
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS Journal of Acquired Immune Deficiency Syndromes, 62(1), 60-66. doi:10.1097/qai.0b013e3182737231
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Efavirenz in an Obese HIV-Infected Patient – a Report and An <i>In Vitro–In Vivo</i> Extrapolation Model Indicate Risk of Underdosing
De Roche, M., Siccardi, M., Stoeckle, M., Livio, F., Back, D., Battegay, M., & Marzolini, C. (2012). Efavirenz in an Obese HIV-Infected Patient – a Report and An <i>In Vitro–In Vivo</i> Extrapolation Model Indicate Risk of Underdosing. Antiviral Therapy, 17(7), 1381-1384. doi:10.3851/imp2107
Effect of Food on the Steady‐State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady‐State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012(1), 105980. doi:10.1155/2012/105980
Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP)
Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336
Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Winston, A., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 56. doi:10.7448/IAS.15.6.18331
Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro
Sandmann, L., Wilson, M., Back, D., Wedemeyer, H., Manns, M. P., Steinmann, E., . . . Ciesek, S. (2012). Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. Antiviral Research, 96(1), 51-58. doi:10.1016/j.antiviral.2012.07.005
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model. Clinical Pharmacology & Therapeutics, 92(4), 494-502. doi:10.1038/clpt.2012.61
Estimation of the Effect of <i>Slco1B1</i> Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the Effect of <i>Slco1B1</i> Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults. Antiviral Therapy, 17(5), 861-868. doi:10.3851/imp2095
Efavirenz Pharmacokinetics in Cerebrospinal Fluid and Plasma over a 24-Hour Dosing Interval
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz Pharmacokinetics in Cerebrospinal Fluid and Plasma over a 24-Hour Dosing Interval. Antimicrobial Agents and Chemotherapy, 56(9), 4583-4585. doi:10.1128/aac.06311-11
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrobial Agents and Chemotherapy, 56(9), 4583-4585.
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207
Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults
Lamorde, M., Byakika-Kibwika, P., Boffito, M., Nabukeera, L., Mayito, J., Ogwal-Okeng, J., . . . Merry, C. (2012). Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes, 60(3), 295-298. doi:10.1097/qai.0b013e3182567a35
Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. Antimicrobial Agents and Chemotherapy, 56(6), 3020-3026. doi:10.1128/aac.06407-11
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
Byakika-Kibwika, P., Lamorde, M., Okaba-Kayom, V., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., . . . Merry, C. (2012). Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 67(5), 1217-1223. doi:10.1093/jac/dkr596
Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF)
Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.
Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Perri, G. D. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. Therapeutic Drug Monitoring, 34(2), 232-235. doi:10.1097/ftd.0b013e31824aa50a
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Journal of Antimicrobial Chemotherapy, 67(3), 675-680. doi:10.1093/jac/dkr491
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Journal of Antimicrobial Chemotherapy, 67(3), 675-680. doi:10.1093/jac/dkr491
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433. doi:10.1128/aac.05599-11
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 56(2), 816-824. doi:10.1128/aac.05186-11
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy, 17(1), 19-24. doi:10.3851/imp1910
Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy
Vera, J. H., Garvey, L. J., Allsop, J. M., Kaye, S., McClure, M. O., Back, D., . . . Winston, A. (2012). Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy. HIV Clinical Trials, 13(4), 222-227. doi:10.1310/hct1304-222
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study
Garvey, L., Nelson, M., Latch, N., Erlwein, O. W., Allsop, J. M., Mitchell, A., . . . Winston, A. (2012). CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. Journal of Antimicrobial Chemotherapy, 67(1), 206-212. doi:10.1093/jac/dkr427
Divalent metals and pH alter raltegravir disposition in vitro.
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent metals and pH alter raltegravir disposition in vitro.. Antimicrobial Agents and Chemotherapy.
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.. Antimicrobial Agents and Chemotherapy, 56, 4583-4585.
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012, 1-6. doi:10.1155/2012/105980
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting
Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2012). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. Journal of Antimicrobial Chemotherapy.
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial Agents and Chemotherapy, 56, 816-824.
Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy, 17(1), 19-24. doi:10.3851/imp1910
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral Therapy., 17, 19-24.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.. Antimicrobial Agents and Chemotherapy, 56, 1427-1433.
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2012). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. Journal of Acquired Immune Deficiency Syndrome.
2011
Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid). Antiviral Therapy, 16(8), 1139-1147. doi:10.3851/imp1918
Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/imp1919
IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients
Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 442-445. doi:10.1097/qai.0b013e318236441c
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67
Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors?
Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors?. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), e137-e138. doi:10.1097/qai.0b013e318237ccae
Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients
Soriano, V., Sherman, K. E., Rockstroh, J., Dieterich, D., Back, D., Sulkowski, M., & Peters, M. (2011). Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients. AIDS, 25(18), 2197-2208. doi:10.1097/qad.0b013e32834bbb90
Directly acting antivirals for hepatitis C and antiretrovirals
Seden, K., & Back, D. (2011). Directly acting antivirals for hepatitis C and antiretrovirals. Current Opinion in HIV and AIDS, 6(6), 514-526. doi:10.1097/coh.0b013e32834b54dc
Ageing with HIV: medication use and risk for potential drug–drug interactions
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Yerly, S. (2011). Ageing with HIV: medication use and risk for potential drug–drug interactions. Journal of Antimicrobial Chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Muller, M. (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy, 66(9), 2092-2098. doi:10.1093/jac/dkr272
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. Antimicrobial Agents and Chemotherapy, 55(9), 4218-4223. doi:10.1128/aac.01747-10
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 66(6), 1332-1339. doi:10.1093/jac/dkr087
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
Ashby, J., Garvey, L., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2011). Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. Journal of Antimicrobial Chemotherapy, 66(6), 1340-1345. doi:10.1093/jac/dkr093
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. Antimicrobial Agents and Chemotherapy, 55(6), 2775-2782. doi:10.1128/aac.00887-10
Cardiac Conduction Safety during Coadministration of Artemether‐Lumefantrine and Lopinavir/Ritonavir in HIV‐Infected Ugandan Adults
Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether‐Lumefantrine and Lopinavir/Ritonavir in HIV‐Infected Ugandan Adults. Chemotherapy Research and Practice, 2011(1), 393976. doi:10.1155/2011/393976
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers
Jackson, A., D'Avolio, A., Watson, V., Bonora, S., Back, D., Taylor, J., . . . Boffito, M. (2011). Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. Journal of Antimicrobial Chemotherapy, 66(4), 885-889. doi:10.1093/jac/dkq546
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/qad.0b013e3283445700
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.
Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort
Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLoS ONE, 6(2), e16800. doi:10.1371/journal.pone.0016800
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. Journal of Antimicrobial Chemotherapy, 66(3), 635-640. doi:10.1093/jac/dkq468
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
Lambert, J., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. Antimicrobial Agents and Chemotherapy, 55(2), 879-887. doi:10.1128/aac.00623-10
. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers
Jackson, A., D'Avolio, A., Watson, V., Bonora, S., Back, D., Taylor, J., . . . Boffito, M. (2011). . Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. Journal of Antimicrobial Chemotherapy, 66, 885-889.
. Pharmacokinetic and safety profile of raltegravir and ribavirin when dosed separately and together in healthy volunteers
Ashby, J., Garvey, L., Erlwein, O. W., Lamba, H., Weston, R., Legg, K., . . . Winston, A. (2011). . Pharmacokinetic and safety profile of raltegravir and ribavirin when dosed separately and together in healthy volunteers. Journal of Antimicrobial Chemotherapy, 66, 1340-1345.
Adipogenic gene variants in patients with HIV-associated lipodystrophy
Pushpakom, S. P., Owen, A., Vilar., Castro, H., Dunn, D. T., Back, D. J., & Pirmohamed, M. (2011). Adipogenic gene variants in patients with HIV-associated lipodystrophy. Pharmacogenetics and Genomics, 21(2), 76-83. doi:10.1097/fpc.0b013e328342a917
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.
Liptrott, N. J., Pushpakom, S., Wyen, C., Fatkenheur, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2011). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.. Pharmacogenetics and genomics.
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden, K., & Back, D. (2011). Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.. Current Opinion in HIV and AIDS, 6, 514-526.
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. Journal of Antimicrobial Chemotherapy., 66, 635-640.
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).. Antiviral Therapy, 16, 1139-1147.
Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over 72 hours following drug cessation
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over 72 hours following drug cessation. Antimicrobial Agents and Chemotherapy, 55, 4218-4223.
Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients
Moltó, J., Valle, M., Back, D., Cedeño, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 55(1), 72-75. doi:10.1128/aac.00789-10
Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients.
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients.. Antimicrobial Agents & Chemotherapy, 55, 72-75.
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. of Acquired Immune Deficiency Syndrome, 58, 450-457.
Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrob Agents & Chemotherapy, 55, 2775-2782.
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25, 722-725.
2010
Grapefruit-Drug Interactions
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000
Grapefruit-Drug Interactions
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men
Randell, P. A., Jackson, A. G., Boffito, M., Back, D. J., Tjia, J. F., Taylor, J., . . . Moyle, G. J. (2010). Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antiviral Therapy, 15(8), 1125-1132. doi:10.3851/imp1675
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenetics and Genomics, 20(12), 759-765. doi:10.1097/fpc.0b013e3283402efb
Pharmacokinetic evaluation of etravirine
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism & Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811
Pharmacokinetic evaluation of etravirine
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism & Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811
Pharmacokinetic evaluation of etravirine.
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine.. Expert opinion on drug metabolism & toxicology, 6(12), 1575-1585.
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10
Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. JAIDS Journal of Acquired Immune Deficiency Syndromes, 55(3), 345-350. doi:10.1097/qai.0b013e3181e9871b
Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men
Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men. AIDS, 24(16), 2583-2587. doi:10.1097/qad.0b013e32833ead18
Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. Journal of Chromatography B, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036
Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy
Evans-Jones, J. G., Cottle, L. E., Back, D. J., Gibbons, S., Beeching, N. J., Carey, P. B., & Khoo, S. H. (2010). Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 50(10), 1419-1421. doi:10.1086/652149
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antiviral Therapy, 15(2), 213-218. doi:10.3851/imp1517
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086
Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes
Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 65(5), 906-916. doi:10.1093/jac/dkq082
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02d
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 cells and primary human lymphocytes
Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 65, 906-916.
Darunavir concentrations exfeed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1 infected men
Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exfeed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1 infected men. AIDS, 24, 2583-2587.
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells
Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. Acta Pharmacologica Sinica, 31(1), 51-65. doi:10.1038/aps.2009.187
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells
Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. Acta Pharmacologica, 31, 51-65.
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Grapefruit juice drug interactions
Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays
Yilmaz, S., Boffito, M., Collot-Teixeira, S., De Lorenzo, F., Waters, L., Fletcher, C., . . . McGregor, J. L. (2010). Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays. Genomics, 96(1), 57-65. doi:10.1016/j.ygeno.2010.03.011
Nevirapine pharmacokinetics when inititate at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
Lamorde, M., Byakika-Kbwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2010). Nevirapine pharmacokinetics when inititate at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66, 180-183.
Pharmacokinetic evaluation of etravirine
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion in Drug Metabolism & Toxicology, 6, 1575-1585.
Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.
Pharmacokinetics and drug–drug interactions of antiretrovirals: An update
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017
Pharmacokinetics and drug–drug interactions of antiretrovirals: An update
Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug–drug interactions of antiretrovirals: An update. Antiviral Research, 85(1), 176-189. doi:10.1016/j.antiviral.2009.07.017
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. Journal of Antimicrobial Chemotherapy.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..
Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2010). Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients. Antimicrobial Agents & Chemotherapy.
Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study
Study, T. S. H. C., Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., . . . Battegay, M. (2010). Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3), 413-423. doi:10.3851/imp1540
Raltegraivr is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir
Moss, D. M., Kwan, W. S., Liptortt, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegraivr is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents & Chemotherapy.
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1 seropositive Ugandan women
Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1 seropositive Ugandan women. Journal of Acquired Immune Deficiency Syndrome, 55, 345-350.
Swiss Cohort Study. Prevelance of codedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furer, H., . . . Battegay, M. (2010). Swiss Cohort Study. Prevelance of codedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15, 413-423.
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. British Journal of Pharmacology, 159, 484-493.
The accumulation and metabolism of zidovudine in 3T3‐F442A pre‐adipocytes
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3‐F442A pre‐adipocytes. British Journal of Pharmacology, 159(2), 484-493. doi:10.1111/j.1476-5381.2009.00552.x
The effects of a nucleoside sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1 infected patients
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1 infected patients. Antiviral Therapy, 15, 213-218.
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey, L., Latch, N., Erlwein, O. W., Mackie, N. E., Walsh, J., Scullard, G., . . . Winston, A. (2010). The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.. Antiviral therapy, 15(2), 213-218.
Validation of a rapid and sensitive high-performance liquid chromatography-tandme mass spectrometry (HPLC-MS/MS) assay for the simulataneous determination of existing and new antiretroviral compounds
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandme mass spectrometry (HPLC-MS/MS) assay for the simulataneous determination of existing and new antiretroviral compounds. Journal of Chromatogr B Analytical Technology Biomedical Life Sciences, 878, 1455-1465.
2009
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir
Janneh, O., Anwar, T., Jungbauer, C., Kopp, S., Khoo, S. H., Back, D. J., & Chiba, P. (2009). P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antiviral Therapy, 14(7), 965-974. doi:10.3851/imp1399
Factors influencing lopinavir and atazanavir plasma concentration
Stohr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2010). Factors influencing lopinavir and atazanavir plasma concentration. Journal of Antimicrobial Chemotherapy, 65(1), 129-137. doi:10.1093/jac/dkp408
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. Journal of Antimicrobial Chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.
Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers
Boffito, M., Jackson, A., Lamorde, M., Back, D., Watson, V., Taylor, J., . . . Pozniak, A. (2009). Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes, 52(2), 222-227. doi:10.1097/qai.0b013e3181b061d0
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 64(5), 1002-1007. doi:10.1093/jac/dkp335
Maraviroc: Pharmacokinetics and drug Interactions
Abel, S., Back, D. J., & Vourvahis, M. (2009). Maraviroc: Pharmacokinetics and drug Interactions. Antiviral Therapy, 14(5), 607-618. doi:10.1177/135965350901400514
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.
Intracellular ‘boosting’ of darunavir using known transport inhibitors in primary PBMC
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular ‘boosting’ of darunavir using known transport inhibitors in primary PBMC. British Journal of Clinical Pharmacology, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.x
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz
Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. Clinical Pharmacology & Therapeutics, 86(2), 204-211. doi:10.1038/clpt.2009.78
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable
Seden, K., Back, D., & Khoo, S. (2009). Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. Journal of Antimicrobial Chemotherapy, 64(1), 5-8. doi:10.1093/jac/dkp152
Etravirine plasma levels in a patient with decompensated liver disease
Aboud, M., Castelino, S., Back, D., & Kulasegaram, R. (2009). Etravirine plasma levels in a patient with decompensated liver disease. AIDS, 23(10), 1293-1295. doi:10.1097/qad.0b013e32832c9fb6
Predictors of Kidney Tubular Dysfunction in HIV‐Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Rodríguez‐Nóvoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV‐Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. Clinical Infectious Diseases, 48(11), e108-e116. doi:10.1086/598507
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial Chemotherapy, 63(6), 1233-1243. doi:10.1093/jac/dkp102
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Medicine, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.x
Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression
Collot-Teixeira, S., De Lorenzo, F., Waters, L., Fletcher, C., Back, D., Mandalia, S., . . . Boffito, M. (2009). Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression. Clinical Pharmacology & Therapeutics, 85(4), 375-378. doi:10.1038/clpt.2008.243
The impact of pharmacogenetics on HIV therapy
Mahungu, T. W., Johnson, M. A., Owen, A., & Back, D. J. (2009). The impact of pharmacogenetics on HIV therapy. International Journal of STD & AIDS, 20(3), 145-151. doi:10.1258/ijsa.2008.008369
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
Liptrott, N., Penny, M., Bray, P., Sathish, J., Khoo, S., Back, D., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons
Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.
Drug-Drug Interactions Involving Antiretrovirals
Seden, K., Back, D. J., & Khoo, S. H. (2009). Drug-Drug Interactions Involving Antiretrovirals. Journal of Antimicrobial Chemotherapy, (in pr.
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry
Liptrott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. Journal of Immunological Methods, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010
Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation
Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation. Antiviral Therapy, 13(7), 901-907. doi:10.1177/135965350801300702
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.. The Journal of antimicrobial chemotherapy, 62(6), 1344-1355.
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals
Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 62(6), 1344-1355. doi:10.1093/jac/dkn399
Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (<i>PXR</i>63396C→T) with Reduced Concentrations of Unboosted Atazanavir
Siccardi, M., D’Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (<i>PXR</i>63396C→T) with Reduced Concentrations of Unboosted Atazanavir. Clinical Infectious Diseases, 47(9), 1222-1225. doi:10.1086/592304
Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir
Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. British Journal of Pharmacology, 155(6), 875-883. doi:10.1038/bjp.2008.320
Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients
Moltó, J., Santos, J. R., Pérez-Álvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. Antimicrobial Agents and Chemotherapy, 52(11), 3928-3932. doi:10.1128/aac.00520-08
Mycophenolate mofetil inhibits T-cell proliferation in kidney transplant recipients without lowering intracellular dGTP and GTP
Sankatsing, S. U. C., Prins, J. M., Yong, S. -L. L., Roelofsen, J., van Kuilenburg, A. B. P., Kewn, S., . . . ten Berge, I. J. M. (2008). Mycophenolate mofetil inhibits T-cell proliferation in kidney transplant recipients without lowering intracellular dGTP and GTP. Transplant International, ???. doi:10.1111/j.1432-2277.2008.00739.x
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults
Byakika-Kibwika, P., Lamorde, M., Kalemeera, F., D'Avolio, A., Mauro, S., Di Perri, G., . . . Merry, C. (2008). Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 62(5), 1113-1117. doi:10.1093/jac/dkn290
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Mallewa, J. E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D., Back, D., & Pirmohamed, M. (2008). HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. Journal of Antimicrobial Chemotherapy, 62(4), 648-660. doi:10.1093/jac/dkn251
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication. Antiviral Therapy, 13(5), 675-685. doi:10.1177/135965350801300507
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes
Jones, S. P., Waitt, C., Sutton, R., Back, D. J., & Pirmohamed, M. (2008). Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS, 22(11), 1293-1298. doi:10.1097/qad.0b013e3283021a4f
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes
Jones, S. P., Waitt, C., Sutton, R., Back, D. J., & Pirmohamed, M. (2008). Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS, 22(11), 1293-1298. doi:10.1097/qad.0b013e3283021a4f
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing
Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187
Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis. Therapeutic Drug Monitoring, 30(3), 306-313. doi:10.1097/ftd.0b013e318177209e
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.
Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis
Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313.
Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects. Clinical Pharmacology & Therapeutics, 83(6), 867-872. doi:10.1038/sj.clpt.6100375
Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV‐infected Subjects
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV‐infected Subjects. Clinical Pharmacology & Therapeutics, 83(6), 867-872. doi:10.1038/sj.clpt.6100375
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
Singh, K., Dickinson, L., Chaikan, A., Back, D., Fletcher, C., Pozniak, A., . . . Boffito, M. (2008). Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.. Clinical pharmacology and therapeutics, 83(6), 867-872.
Influence of Environmental Chemicals on Drug Therapy in Humans: Studies with Contraceptive Steroids
Breckenridge, A. M., Back, D. J., Cross, K., Crawford, F., MacIver, M., L'E Orme, M., . . . Smith, E. (1980). Influence of Environmental Chemicals on Drug Therapy in Humans: Studies with Contraceptive Steroids. In Unknown Book (pp. 289-306). Wiley. doi:10.1002/9780470720592.ch16
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/coh.0b013e3282f82bf1
Darunavir: Pharmacokinetics and Drug Interactions
Back, D., Sekar, V., & Hoetelmans, R. M. W. (2008). Darunavir: Pharmacokinetics and Drug Interactions. Antiviral Therapy, 13(1), 1-14. doi:10.1177/135965350801300101
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 61(4), 914-918. doi:10.1093/jac/dkn029
Response to ‘Communicating Information about Drug Interactions’
Back, D. J., & Gibbons, S. E. (2008). Response to ‘Communicating Information about Drug Interactions’. British Journal of Clinical Pharmacology, 65(4), 617-618. doi:10.1111/j.1365-2125.2007.03043.x
Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells
Martin, P., Riley, R., Back, D. J., & Owen, A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. British Journal of Pharmacology, 153(4), 805-819. doi:10.1038/sj.bjp.0707601
Differences in pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.
Dickinson, L., Khoo, S., & Back, D. (2008). Differences in pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.. Current Opinion in HIV & AIDS, 3, 296-305.
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication. Antiviral Therapy, 13(5), 675-685.
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation
Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.
2007
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification
Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. Journal of Antimicrobial Chemotherapy, 60(4), 881-884. doi:10.1093/jac/dkm281
A rapid and sensitive HPLC–MS method for the detection of plasma and cellular rifampicin
HARTKOORN, R., KHOO, S., BACK, D., TJIA, J., WAITT, C., CHAPONDA, M., . . . WARD, S. (2007). A rapid and sensitive HPLC–MS method for the detection of plasma and cellular rifampicin. Journal of Chromatography B, 857(1), 76-82. doi:10.1016/j.jchromb.2007.07.005
Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects
Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. Journal of Antimicrobial Chemotherapy, 60(3), 685-689. doi:10.1093/jac/dkm230
Stopping antiretroviral therapy
Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy. AIDS, 21(13), 1673-1682. doi:10.1097/qad.0b013e3281c61394
Limited-Sampling Strategy for the Prediction of Boosted Hard-Gel Saquinavir Exposure at a Dosage of 1000/100 mg Twice Daily in Human Immunodeficiency Virus-Infected Individuals
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-Sampling Strategy for the Prediction of Boosted Hard-Gel Saquinavir Exposure at a Dosage of 1000/100 mg Twice Daily in Human Immunodeficiency Virus-Infected Individuals. Therapeutic Drug Monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.
Combining resistance and pharmacology for optimum patient care
Khoo, S. H., Winston, A., & Back, D. J. (2007). Combining resistance and pharmacology for optimum patient care. Current Opinion in HIV and AIDS, 2(3), 157-168. doi:10.1097/coh.0b013e3280f31d27
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein
Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Bertel Squire, S., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001
Response to ‘Nifedipine–lopinavir/ritonavir severe interaction: a case report’
Back, D. J., & Gibbons, S. E. (2007). Response to ‘Nifedipine–lopinavir/ritonavir severe interaction: a case report’. AIDS, 21(9), 1226-1227. doi:10.1097/qad.0b013e32811ebf8e
Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients
Waters, L. J., Moyle, G., Bonora, S., D'Avolio, A., Else, L., Mandalia, S., . . . Boffito, M. (2007). Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients. Antiviral Therapy, 12(5), 825-830. doi:10.1177/135965350701200510
Effect of Transporter Modulation on the Emergence of Nelfinavir Resistance <i>In Vitro</i>
Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of Transporter Modulation on the Emergence of Nelfinavir Resistance <i>In Vitro</i>. Antiviral Therapy, 12(5), 831-834. doi:10.1177/135965350701200515
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Ther Drug Monitoring, 29(3), 361-367.
Nifedipine-lopinavir/ritonavir severe interaction:a case report.
Back, D. J., & Gibbons, S. E. (2007). Nifedipine-lopinavir/ritonavir severe interaction:a case report.. AIDS, 21(9), 1226-1227.
2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 58(5), 1009-1016. doi:10.1093/jac/dkl379
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug
Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. Annals of the Rheumatic Diseases, 65(10), 1390-1393. doi:10.1136/ard.2005.049189
Pharmacogenetics of HIV therapy
Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. Pharmacogenetics and Genomics, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57
Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses. AIDS Research and Human Retroviruses, 22(8), 749-756. doi:10.1089/aid.2006.22.749
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2006). Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.. AIDS research and human retroviruses, 22(8), 749-756.
An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs
Back, D., Gibbons, S., & Khoo, S. (2006). An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs. Therapeutic Drug Monitoring, 28(3), 468-473. doi:10.1097/01.ftd.0000211825.57984.41
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers
Winston, A., Back, D., Fletcher, C., Robinson, L., Unsworth, J., Tolowinska, I., . . . Boffito, M. (2006). Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS, 20(10), 1401-1406. doi:10.1097/01.aids.0000233573.41597.8a
Different Methods to Calculate the Inhibitory Qoutient of Boosted Single Protease Inhibitors and Their Association With Virological Response
Winston, A., Patel, N., Back, D., Khoo, S., Bulbeck, S., Mandalia, S., . . . Boffito, M. (2006). Different Methods to Calculate the Inhibitory Qoutient of Boosted Single Protease Inhibitors and Their Association With Virological Response. JAIDS Journal of Acquired Immune Deficiency Syndromes, 41(5), 675-676. doi:10.1097/01.qui.0000209910.27997.d9
Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support
Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support. JAIDS Journal of Acquired Immune Deficiency Syndromes, 41(4), 461-467. doi:10.1097/01.qai.0000218345.65434.21
Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals
Back, D. J., Owen, A., & Khoo, S. H. (2006). Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals. Clinical Pharmacokinetics, 45(2), 213-214. doi:10.2165/00003088-200645020-00006
Drug-drug interactions that matter.
Back, D. J. (2006). Drug-drug interactions that matter.. Topics in antiviral medicine, 14(2), 88-92.
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers
Winston, A., Back, D., Fletcher, C., Robinson, L., Unsworth, J., Tolowinska, I., . . . Boffito, M. (2006). Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS, 20(10), 401-406.
Pharmacokinetics of reverse transcriptase inhibitors
Hoggard, P., Kewn, S., Khoo, S., & Back, D. (2006). Pharmacokinetics of reverse transcriptase inhibitors. In G. Skowron, & R. Ogden (Eds.), Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (pp. xxx). Totowa, New Jersey: Humana Press.
Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.
Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.. J Acquir Immune Defic Syndr, 41(4), 461-467.
2005
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.
Assessment of Adipokine Expression and Mitochondrial Toxicity in HIV Patients With Lipoatrophy on Stavudine- and Zidovudine-Containing Regimens
Jones, S. P., Qazi, N., Morelese, J., Lebrecht, D., Sutinen, J., Yki-Jărvinen, H., . . . Moyle, G. J. (2005). Assessment of Adipokine Expression and Mitochondrial Toxicity in HIV Patients With Lipoatrophy on Stavudine- and Zidovudine-Containing Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(5), 565-572. doi:10.1097/01.qai.0000187443.30838.3e
Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study
Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., . . . Back, D. (2005). Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 49(10), 3997-4008. doi:10.1128/aac.49.10.3997-4008.2005
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 56(4), 738-744. doi:10.1093/jac/dki308
In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine. The Journal of Pharmacology and Experimental Therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals
ALMOND, L., EDIRISINGHE, D., DALTON, M., BONINGTON, A., BACK, D., & KHOO, S. (2005). Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clinical Pharmacology & Therapeutics, 78(2), 132-142. doi:10.1016/j.clpt.2005.04.004
The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Back, D. J., Burger, D. M., Flexner, C. W., & Gerber, J. G. (2005). The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 39(Supplement 1), S1-S23. doi:10.1097/01.qai.0000168882.67942.3f
The potential for interactions between antimalarial and antiretroviral drugs
Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs. AIDS, 19(10), 995-1005. doi:10.1097/01.aids.0000174445.40379.e0
The potential for interactions between antimalarial and antiretroviral drugs
Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs. AIDS, 19(10), 995-1005.
The implications of P‐glycoprotein in HIV: friend or foe?
Owen, A., Chandler, B., & Back, D. J. (2005). The implications of P‐glycoprotein in HIV: friend or foe?. Fundamental & Clinical Pharmacology, 19(3), 283-296. doi:10.1111/j.1472-8206.2005.00324.x
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., . . . Pozniak, A. (2005). Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. Journal of Antimicrobial Chemotherapy, 55(4), 542-545. doi:10.1093/jac/dki043
Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors
Jones, S. P., Janneh, O., Back, D. J., & Pirmohamed, M. (2005). Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy, 10(2), 207-213. doi:10.1177/135965350501000202
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens
Jones, S. P., Qazi, N., Morelese, J., Lebrecht, D., Sutinen, J., Yki-Jarvinen, H., . . . Moyle, G. J. (2005). Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. Journal of Acquired Immune Deficiency Syndromes, 40, 562-572.
Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy
Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., . . . Back, D. (2005). Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy. Antiviral Therapy, 10(3), 375-392. doi:10.1177/135965350501000307
Drug efflux transporters in rheumatoid arthritis: Comment on the article by Kremer
Hider, S. L., Hoggard, P., Khoo, S., Back, D., & Bruce, I. N. (2005). Drug efflux transporters in rheumatoid arthritis: Comment on the article by Kremer. Arthritis & Rheumatism, 52(2), 670. doi:10.1002/art.20770
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.
Intracellular accumulation of human immunodeficiency virus protease inhibitors
Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., . . . Back, D. (2005). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antiviral Therapy, 10, 3228-3235. doi:10.1128/AAC.46.10.3228-3235.2002
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.. AIDS, 19(18), 2097-2102. Retrieved from http://gateway.ut.ovid.com/
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV‐1‐infected subjects
Boffito, M., Back, D., Stainsby‐Tron, M., Hill, A., Di Perri, G., Moyle, G., . . . Pozniak, A. (2005). Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV‐1‐infected subjects. British Journal of Clinical Pharmacology, 59(1), 38-42. doi:10.1111/j.1365-2125.2004.02240.x
Similtaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Dickinson, L., Robinson, L., Tjia, J., Khoo, S. H., & Back, D. (2005). Similtaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir in human plasma by high performance liquid chromatography-tandem mass spectrometry.. J Chromatogr B, 831, 258-266.
Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs
Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., . . . Back, D. (2005). Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs. Antiviral Therapy, 10(4), 469-477. doi:10.1177/135965350501000413
2004
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients
Perucca, E., Hedges, A., Makki, K. A., Ruprah, M., Wilson, J. F., Richens, A., & Back, D. (2004). A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. British Journal of Clinical Pharmacology, 58(7 SPEC. ISS.).
Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4. Journal of Virology, 78(21), 12022-12029. doi:10.1128/jvi.78.21.12022-12029.2004
Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1a
Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 37(3), 1376-1384. doi:10.1097/01.qai.0000136060.65716.1a
Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools
Sankatsing, S. U. C., Hoggard, P. G., Huitema, A. D. R., Sparidans, R. W., Kewn, S., Crommentuyn, K. M. L., . . . Prins, J. M. (2004). Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools. Clinical Pharmacokinetics, 43(12), 823-832. doi:10.2165/00003088-200443120-00004
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen
Isaac, A. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. Journal of Antimicrobial Chemotherapy, 54(2), 498-502. doi:10.1093/jac/dkh357
Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients
Ford, J., Boffito, M., Wildfire, A., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2004). Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 48(7), 2388-2393. doi:10.1128/aac.48.7.2388-2393.2004
The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests
Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests. AIDS Research and Human Retroviruses, 20(7), 716-722. doi:10.1089/0889222041524670
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral therapy, 9(3), 423-429.
Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance
Mackie, N. E., Fidler, S., Tamm, N., Clarke, J. R., Back, D., Weber, J. N., & Taylor, G. P. (2004). Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Medicine, 5(3), 180-184. doi:10.1111/j.1468-1293.2004.00208.x
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Winston, A., Pozniak, A., Smith, N., Fletcher, C., Mandalia, S., Parmar, D., . . . Nelson, M. (2004). Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?. AIDS, 18(3), 572-574. doi:10.1097/00002030-200402200-00029
Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval
Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval. Therapeutic Drug Monitoring, 26(1), 35-39. doi:10.1097/00007691-200402000-00008
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients
Perucca, E., Hedges, A., Makki, K. A., Ruprah, M., Wilson, J. F., & Richens, A. (2004). A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. British Journal of Clinical Pharmacology, 58(7). doi:10.1111/j.1365-2125.2004.02311.x
Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna. Antiviral Therapy, 9(5), 819-821. doi:10.1177/135965350400900510
Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.. Antiviral Therapy, 9(5), 819-821.
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.
Intracellular Accumulation of Nelfinavir and Its Relationship to P-Glycoprotein Expression and Function in HIV-Infected Patients
Hennessy, M., Clarke, S., Spiers, J. P., Kelleher, D., Mulcahy, F., Hoggard, P., . . . Barry, M. (2004). Intracellular Accumulation of Nelfinavir and Its Relationship to P-Glycoprotein Expression and Function in HIV-Infected Patients. Antiviral Therapy, 9(1), 115-122. doi:10.1177/135965350400900103
Intracellular and Plasma Pharmacokinetics of Nelfinavir and M8 in HIV-Infected Patients: Relationship with P-Glycoprotein Expression
Ford, J., Cornforth, D., Hoggard, P. G., Cuthbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and Plasma Pharmacokinetics of Nelfinavir and M8 in HIV-Infected Patients: Relationship with P-Glycoprotein Expression. Antiviral Therapy, 9(1), 77-84. doi:10.1177/135965350400900101
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford, J., Cornforth, D., Hoggard, P. G., Cutherbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.. Antiviral Therapy, 9(1), 77-84.
Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-α and Tnf-Receptor Levels, and on Metabolic Parameters
Maher, B., Lloyd, J., Wilkins, E. G. L., Fraser, W. D., Back, D., Park, B. K., & Pirmohamed, M. (2004). Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-α and Tnf-Receptor Levels, and on Metabolic Parameters. Antiviral Therapy, 9(6), 879-887. doi:10.1177/135965350400900601
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen
Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S., White, D. J., . . . Back, D. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother, 54(2), 498-502.
Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen. Antiviral Therapy, 9(3), 423-429. doi:10.1177/135965350400900315
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
Boffito, M., Dicckinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.. Antiviral Therapy, 9(3), 423-429.
Pharmacology update: drug-drug interactions and ethnic and sex differences.
Back, D. J., Dickinson, L., Canta, F., & Khoo, S. (2004). Pharmacology update: drug-drug interactions and ethnic and sex differences.. HIV/AIDS Annual Update 2004.
Steady-state pharmacokinetics of saquinavair hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., . . . Pozniak, A. (2004). Steady-state pharmacokinetics of saquinavair hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.. Journal of Acquired Immune Deficiency Syndrome., 37(3), 1376-1384.
The intracellular pharmacology of antiretroviral protease inhibitors
Ford, J., Khoo, S. H., & Back, D. J. (2004). The intracellular pharmacology of antiretroviral protease inhibitors. Journal of Antimicrobial Chemotherapy.
2003
Treating Advanced HIV Infection
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating Advanced HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3), 344-345. doi:10.1097/00126334-200311010-00014
Treating Advanced HIV Infection
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating Advanced HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3), 344-345. doi:10.1097/00126334-200311010-00014
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines
Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024
Ketoconazole and Lopinavir/Ritonavir Coadministration: Boosting beyond Boosting
Boffito, M., Bonora, S., Sales, P., Dal Conte, I., Sinicco, A., Hoggard, P. G., . . . Di Perri, G. (2003). Ketoconazole and Lopinavir/Ritonavir Coadministration: Boosting beyond Boosting. AIDS Research and Human Retroviruses, 19(10), 941-942. doi:10.1089/088922203322493148
Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression
Ford, J. (2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. Journal of Antimicrobial Chemotherapy, 52(3), 354-358. doi:10.1093/jac/dkg381
Pharmacokinetic Drug Interactions with Nevirapine
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic Drug Interactions with Nevirapine. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34, S8-S14. doi:10.1097/00126334-200309011-00003
Protein Binding in Antiretroviral Therapies
Boffito, M., Back, D. J., Blaschke, T. F., Rowland, M., Bertz, R. J., Gerber, J. G., & Miller, V. (2003). Protein Binding in Antiretroviral Therapies. AIDS Research and Human Retroviruses, 19(9), 825-835. doi:10.1089/088922203769232629
The Effects of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors on P-Glycoprotein Expression in Peripheral Blood Mononuclear Cells In Vitro
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The Effects of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors on P-Glycoprotein Expression in Peripheral Blood Mononuclear Cells In Vitro. JAIDS Journal of Acquired Immune Deficiency Syndromes, 33(5), 551-556. doi:10.1097/00126334-200308150-00001
A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy
Sephton, V. (2003). A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstetrics & Gynecology, 101(6), 1307-1311. doi:10.1016/s0029-7844(03)00340-5
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring
Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/00002030-200305020-00029
The role of clinical pharmacology in optimizing antiretroviral therapy
Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. British Journal of Clinical Pharmacology, 55(5), 473-476. doi:10.1046/j.1365-2125.2003.01843.x
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets
Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. Journal of Immunological Methods, 274(1-2), 129-137. doi:10.1016/s0022-1759(02)00509-4
Differential Expression of Human Immunodeficiency Virus Coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub>Cells
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential Expression of Human Immunodeficiency Virus Coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub>Cells. The Journal of Infectious Diseases, 187(5), 874-875. doi:10.1086/367902
Lopinavir/ritonavir absorption in a gastrectomized patient
Boffito, M., Lucchini, A., Maiello, A., Dal Conte, I., Hoggard, P. G., Back, D. J., & Di Perri, G. (2003). Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS, 17(1), 136-137. doi:10.1097/00002030-200301030-00023
Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients
Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., . . . Back, D. J. (2003). Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrobial Agents and Chemotherapy, 47(1), 255-261. doi:10.1128/aac.47.1.255-261.2003
Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes
Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes. Antiviral Therapy, 8(5), 417-426. doi:10.1177/135965350300800509
Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics
Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meadon, E., . . . Barry, M. (2003). Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics. Antiviral Therapy, 8(3), 191-198. doi:10.1177/135965350300800302
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes
Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther, 8(5), 417-426. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14640389
Intracellular disposition and metabolic effects of zidovudine, stavudine, and four protease inhibitors in cultured adipocytes
Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine, and four protease inhibitors in cultured adipocytes. Antiviral Therapy, 8(5), 417-426.
Intracellular indinavir pharmacokinetics in HIV-infected patients; comparison with plasma pharmacokinetics.
Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meaden, E., . . . Barry, M. (2003). Intracellular indinavir pharmacokinetics in HIV-infected patients; comparison with plasma pharmacokinetics.. Antiviral Therapy, 8, 191-198.
Lopinavir/ritonavir absorption in a gastrectomized patient
Boffito, M., Lucchini, A., Maiello, A., Dal Conte, I., Hoggard, P. G., Back, D. J., & Di Perri, G. (2003). Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS, 17(1), 136-137. doi:10.1097/00002030-200301030-00023
Pharmacokinetic drug interactions with nevirapine
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr, 34 Sup, S8-S14. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562853
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . diPerri, G. (2003). The relationship between nevirapine plasma concentrations and abnormal liver function tests.. AIDS Research and Human Retroviruses, 20, 716-720.
2002
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea
Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. doi:10.1097/00002030-200212060-00009
Pharmacokinetics of saquinavir co-administered with cimetidine
Boffito, M. (2002). Pharmacokinetics of saquinavir co-administered with cimetidine. Journal of Antimicrobial Chemotherapy, 50(6), 1081-1084. doi:10.1093/jac/dkf232
Lopinavir Measurement in Pleural Effusion in a Human Immunodeficiency Virus Type 1-Infected Patient with Kaposi's Sarcoma
Boffito, M., Hoggard, P. G., Back, D. J., Bonora, S., Maiello, A., Lucchini, A., & Di Perri, G. (2002). Lopinavir Measurement in Pleural Effusion in a Human Immunodeficiency Virus Type 1-Infected Patient with Kaposi's Sarcoma. Antimicrobial Agents and Chemotherapy, 46(11), 3684-3685. doi:10.1128/aac.46.11.3684-3685.2002
Clinical use of lopinavir/ritonavir in a salvage therapy setting
Boffito, M., Arnaudo, I., Raiteri, R., Bonora, S., Sinicco, A., Di Garbo, A., . . . Perri, G. D. (2002). Clinical use of lopinavir/ritonavir in a salvage therapy setting. AIDS, 16(15), 2081-2083. doi:10.1097/00002030-200210180-00015
Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors
Khoo, S. H., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. J. (2002). Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 46(10), 3228-3235. doi:10.1128/aac.46.10.3228-3235.2002
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals
Meaden, E. R. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 50(4), 583-588. doi:10.1093/jac/dkf161
Simultaneous Determination of Rifampicin and Efavirenz in Plasma
Boffito, M., Tija, J., Reynolds, H. E., Hoggard, P. G., Bonora, S., Di Perri, G., & Back, D. J. (2002). Simultaneous Determination of Rifampicin and Efavirenz in Plasma. Therapeutic Drug Monitoring, 24(5), 670-674. doi:10.1097/00007691-200210000-00015
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects
Boffito, M., Hoggard, P. G., Reynolds, H. E., Bonora, S., Meaden, E. R., Sinicco, A., . . . Back, D. J. (2002). The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. British Journal of Clinical Pharmacology, 54(3), 262-268. doi:10.1046/j.1365-2125.2002.01663.x
The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir Is Associated With Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA
Margolis, D. M., Kewn, S., Coull, J. J., Ylisastigui, L., Turner, D., Wise, H., . . . Back, D. (2002). The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir Is Associated With Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA. JAIDS Journal of Acquired Immune Deficiency Syndromes, 31(1), 45-49. doi:10.1097/00126334-200209010-00006
Pharmacokinetic Evaluation of Indinavir and Indinavir/Ritonavir-Containing Antiretroviral Regimens in a Clinical Setting
Boffito, M., Bonora, S., Raiteri, R., Reynolds, H. E., Hoggard, P. G., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetic Evaluation of Indinavir and Indinavir/Ritonavir-Containing Antiretroviral Regimens in a Clinical Setting. Therapeutic Drug Monitoring, 24(4), 574-576. doi:10.1097/00007691-200208000-00021
α1-Acid Glycoprotein Levels in Human Immunodeficiency Virus-Infected Subjects on Antiretroviral Regimens
Boffito, M., Sciolè, K., Raiteri, R., Bonora, S., Hoggard, P. G., Back, D. J., & Di Perri, G. (2002). α1-Acid Glycoprotein Levels in Human Immunodeficiency Virus-Infected Subjects on Antiretroviral Regimens. Drug Metabolism and Disposition, 30(7), 859-860. doi:10.1124/dmd.30.7.859
Therapeutic Drug Monitoring
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic Drug Monitoring. Journal of the International Association of Physicians in AIDS Care, 1(3), 84-85. doi:10.1177/154510970200100301
Multidrug resistance and response to antiretroviral treatment
Dietrich, C. G., Geier, A., Matern, S., & Gartung, C. (2002). Multidrug resistance and response to antiretroviral treatment. The Lancet, 359(9323), 2114. doi:10.1016/s0140-6736(02)08921-3
Intracellular carbovir triphosphate levels in patients taking abacavir once a day
Harris, M., Back, D., Kewn, S., Jutha, S., Marina, R., & Montaner, J. S. G. (2002). Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS, 16(8), 1196-1197. doi:10.1097/00002030-200205240-00021
Therapeutic drug monitoring in HIV infection: current status and future directions
Back, D., Gatti, G., Fletcher, C., Garaffo, R., Haubrich, R., Hoetelmans, R., . . . Perno, C. -F. (2002). Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS, 16, S5-S37. doi:10.1097/00002030-200203001-00002
Absence of Opioid Withdrawal Symptoms in Patients Receiving Methadone and the Protease Inhibitor Lopinavir‐Ritonavir
Clarke, S., Mulcahy, F., Bergin, C., Reynolds, H., Boyle, N., Barry, M., & Back, D. J. (2002). Absence of Opioid Withdrawal Symptoms in Patients Receiving Methadone and the Protease Inhibitor Lopinavir‐Ritonavir. Clinical Infectious Diseases, 34(8), 1143-1145. doi:10.1086/339541
Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo
Meaden, E. R., Hoggard, P. G., Khoo, S. H., & Back, D. J. (2002). Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. Journal of Immunological Methods, 262(1-2), 159-165. doi:10.1016/s0022-1759(02)00020-0
Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354))
Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2002). Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354)). Journal of Antimicrobial Chemotherapy, 49(1), 227.
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir<i>in vitro</i>
Eagling, V. A., Wiltshire, H., Whitcombe, I. W. A., & Back, D. J. (2002). CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir<i>in vitro</i>. Xenobiotica, 32(1), 1-17. doi:10.1080/00498250110085845
Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients
Kewn, S., Hoggard, P. G., Sales, S. D., Jones, K., Maher, B., Khoo, S. H., & Back, D. J. (2002). Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 46(1), 135-143. doi:10.1128/aac.46.1.135-143.2002
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. -P., . . . Telenti, A. (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. The Lancet, 359(9300), 30-36. doi:10.1016/s0140-6736(02)07276-8
Intracellular accumulation of human immunodeficiency virus protease inhibitors
Khoo, S., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother, 46(10), 3228-3235.
Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules
Hoggard, P. G., & Back, D. J. (2002). Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Current Opinion in Infectious Diseases, 15(1), 3-8. doi:10.1097/00001432-200202000-00002
Observations of HIV-1 Genotypic Drug Resistance in a Trial of Four Reverse Transcriptase Inhibitors (Quattro Trial)
Kaye, S., Dunn, D. T., Babiker, A. G., Darbyshire, J. H., Hooker, M. H., Nesarantnam, S., . . . Withnall, R. (2002). Observations of HIV-1 Genotypic Drug Resistance in a Trial of Four Reverse Transcriptase Inhibitors (Quattro Trial). Antiviral Therapy, 7(1), 11-20. doi:10.1177/135965350200700102
Short Communication: Undefined Duration of Opiate Withdrawal Induced by Efavirenz in Drug Users with HIV Infection and Undergoing Chronic Methadone Treatment
Boffito, M., Rossati, A., Reynolds, H. E., Hoggard, P. G., Back, D. J., & Di Perri, G. (2002). Short Communication: Undefined Duration of Opiate Withdrawal Induced by Efavirenz in Drug Users with HIV Infection and Undergoing Chronic Methadone Treatment. AIDS Research and Human Retroviruses, 18(5), 341-342. doi:10.1089/088922202753519115
Therapeutic Drug Monitoring in HIV infection:current status and future directions.
Back, D. J., Gatti, G., Fletcher, C., Garaffo, R., Haubrich, R., Hoetelmans, R., . . . Perno, C. F. (2002). Therapeutic Drug Monitoring in HIV infection:current status and future directions.. AIDS, 16(Suppl), S1-S35.
Therapeutic drug monitoring
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring. J Int Assoc Physicians AIDS Care (Chic), 1(3), 84-85.
2001
Principles and practice of HIV‐protease inhibitor pharmacoenhancement
Moyle, G. J., & Back, D. (2001). Principles and practice of HIV‐protease inhibitor pharmacoenhancement. HIV Medicine, 2(2), 105-113. doi:10.1046/j.1468-1293.2001.00063.x
Therapeutic drug monitoring as a tool in treating HIV infection
Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15, S171-S181. doi:10.1097/00002030-200100005-00021
Zidovudine Phosphorylation and Mitochondrial Toxicity in Vitro
Sales, S. D., Hoggard, P. G., Sunderland, D., Khoo, S., Hart, C. A., & Back, D. J. (2001). Zidovudine Phosphorylation and Mitochondrial Toxicity in Vitro. Toxicology and Applied Pharmacology, 177(1), 54-58. doi:10.1006/taap.2001.9288
Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users. Clinical Infectious Diseases, 33(9), 1595-1597. doi:10.1086/322519
Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men
Taylor, S., Reynolds, H., Sabin, C. A., Drake, S. M., White, D. J., Back, D. J., & Pillay, D. (2001). Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS, 15(15), 2051-2053. doi:10.1097/00002030-200110190-00022
<i>Short Communication:</i> Expression of P-Glycoprotein and Multidrug Resistance-Associated Protein in Healthy Volunteers and HIV-Infected Patients
Meaden, E. R., Hoggard, P. G., Maher, B., Khoo, S. H., & Back, D. J. (2001). <i>Short Communication:</i> Expression of P-Glycoprotein and Multidrug Resistance-Associated Protein in Healthy Volunteers and HIV-Infected Patients. AIDS Research and Human Retroviruses, 17(14), 1329-1332. doi:10.1089/08892220152596588
P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones, K., Bray, P. G., Khoo, S. H., Davey, R. A., Meaden, E. R., Ward, S. A., & Back, D. J. (2001). P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. AIDS, 15(11), 1353-1358. doi:10.1097/00002030-200107270-00004
The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz. British Journal of Clinical Pharmacology, 51(3), 213-217. doi:10.1046/j.1365-2125.2001.00342.x
The role of therapeutic drug monitoring in treatment of HIV infection
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. British Journal of Clinical Pharmacology, 51(4), 301-308. doi:10.1046/j.1365-2125.2001.01380.x
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport
Jones, K., Hoggard, P. G., Sales, S. D., Khoo, S., Davey, R., & Back, D. J. (2001). Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS, 15(6), 675-681. doi:10.1097/00002030-200104130-00002
Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents
Hoggard, P. G., Lloyd, J., Khoo, S. H., Barry, M. G., Dann, L., Gibbons, S. E., . . . Back, D. J. (2001). Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents. Antimicrobial Agents and Chemotherapy, 45(3), 976-980. doi:10.1128/aac.35.3.976-980.2001
Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir
Holladay, J. W., Dewey, M. J., Michniak, B. B., Wiltshire, H., Halberg, D. L., Weigl, P., . . . Back, D. J. (2001). Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir. Drug Metabolism and Disposition, 29(3), 299-303. doi:10.1124/dmd.29.3.299
Effect of α<sub>1</sub>‐acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i>
Jones, K., Hoggard, P. G., Khoo, S., Maher, B., & Back, D. J. (2001). Effect of α<sub>1</sub>‐acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i>. British Journal of Clinical Pharmacology, 51(1), 99-102. doi:10.1046/j.1365-2125.2001.01324.x
Influence of Prior Exposure to Zidovudine on Stavudine Phosphorylation In Vivo and Ex Vivo
Hoggard, P. G., Sales, S. D., Phiboonbanakit, D., Lloyd, J., Maher, B. A., Khoo, S. H., . . . Back, D. J. (2001). Influence of Prior Exposure to Zidovudine on Stavudine Phosphorylation In Vivo and Ex Vivo. Antimicrobial Agents and Chemotherapy, 45(2), 577-582. doi:10.1128/aac.45.2.577-582.2001
The pharmacogenomics of HIV therapy
Pirmohamed, M., & Back, D. J. (2001). The pharmacogenomics of HIV therapy. The Pharmacogenomics Journal, 1(4), 243-253. doi:10.1038/sj.tpj.6500069
The role of therapeutic drug monitoring in treatment of HIV infection
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. British Journal of Clinical Pharmacology, 52, 89-96. doi:10.1046/j.1365-2125.2001.00380.x
Therapeutic drug monitoring of anti-HIV drugs
Back, D. J., Khoo, S. H., Gibbons, S. E., Reynolds, H., Tjia, J. F., & Merry, C. (2001). Therapeutic drug monitoring of anti-HIV drugs. International Congress Series, 1220, 145-160. doi:10.1016/s0531-5131(01)00294-1
2000
The intracellular activation of lamivudine (3TC) and determination of 2′‐deoxycytidine‐5′‐triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells
Kewn,, S., Hoggard,, P. G., Sales,, D., Johnson, A., & Back, D. J. (2000). The intracellular activation of lamivudine (3TC) and determination of 2′‐deoxycytidine‐5′‐triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. British Journal of Clinical Pharmacology, 50(6), 597-604. doi:10.1046/j.1365-2125.2000.00302.x
Commentary
Back, D. J. (2000). Commentary. In Unknown Book (Vol. 50, pp. 85). Wiley. doi:10.1046/j.1365-2125.2000.00246.x
Pharmacokinetics of Zidovudine Phosphorylation in Human Immunodeficiency Virus-Positive Thai Patients and Healthy Volunteers
Wattanagoon, Y., Bangchang, K. N., Hoggard, P. G., Khoo, S. H., Gibbons, S. E., Phiboonbhanakit, D., . . . Back, D. J. (2000). Pharmacokinetics of Zidovudine Phosphorylation in Human Immunodeficiency Virus-Positive Thai Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 44(7), 1986-1989. doi:10.1128/aac.44.7.1986-1989.2000
Pharmacological implications of lengthened in-utero exposure to nevirapine
Taylor, G. P., Lyall, E. G. H., Back, D., Ward, C., & Tudor-Williams, G. (2000). Pharmacological implications of lengthened in-utero exposure to nevirapine. The Lancet, 355(9221), 2134-2135. doi:10.1016/s0140-6736(00)02383-7
Therapeutic Drug Monitoring of Antiretrovirals in Human Immunodeficiency Virus Infection
Back, D. J., Khoo, S. H., Gibbons, S. E., Barry, M. G., & Merry, C. (2000). Therapeutic Drug Monitoring of Antiretrovirals in Human Immunodeficiency Virus Infection. Therapeutic Drug Monitoring, 22(1), 122-126. doi:10.1097/00007691-200002000-00026
Correlation between Intracellular Pharmacological Activation of Nucleoside Analogues and HIV Suppression<i>in Vitro</i>
Hoggard, P. G., Sales, S. D., Kewn, S., Sunderland, D., Khoo, S. H., Hart, C. A., & Back, D. J. (2000). Correlation between Intracellular Pharmacological Activation of Nucleoside Analogues and HIV Suppression<i>in Vitro</i>. Antiviral Chemistry and Chemotherapy, 11(6), 353-358. doi:10.1177/095632020001100601
Current uses and future hopes for clinical pharmacology in the management of HIV infection
Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection. HIV Medicine, 1(s2), 12-17. doi:10.1046/j.1468-1293.2000.00001.x
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis
Taylor, S. (2000). Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy, 45(5), 716-717. doi:10.1093/jac/45.5.716
Re: 'Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir'.
Back, D. J. (2000). Re: 'Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir'.. British journal of clinical pharmacology, 50(2), 85. doi:10.1046/j.1365-2125.2000.00246.x
1999
Effect of tuberculosis therapy on nevirapine trough plasma concentrations
Dean, G. L., Back, D. J., & de Ruiter, A. (1999). Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS, 13(17), 2489. doi:10.1097/00002030-199912030-00029
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
Profit, L., Eagling, V. A., & Back, D. J. (1999). Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS, 13(13), 1623-1627. doi:10.1097/00002030-199909100-00004
Inhibition of the CYP3A4‐mediated metabolism and P‐glycoprotein‐mediated transport of the HIV‐1 protease inhibitor saquinavir by grapefruit juice components
Eagling., Profit., & Back. (1999). Inhibition of the CYP3A4‐mediated metabolism and P‐glycoprotein‐mediated transport of the HIV‐1 protease inhibitor saquinavir by grapefruit juice components. British Journal of Clinical Pharmacology, 48(4), 543-552. doi:10.1046/j.1365-2125.1999.00052.x
Pharmacological issues relating to viral resistance
Back, D. J. (1999). Pharmacological issues relating to viral resistance. In Infection Vol. 27 (pp. S42-S44). Springer Science and Business Media LLC. doi:10.1007/bf02561671
Hydroxyurea-induced neurotoxicity in HIV disease
Barry, M., Clarke, S., Mulcahy, F., & Back, D. (1999). Hydroxyurea-induced neurotoxicity in HIV disease. AIDS, 13(12), 1592. doi:10.1097/00002030-199908200-00028
The Rabbit Study: Ritonavir and Saquinavir in Combination in Saquinavir-Experienced and Previously Untreated Patients
Churchill, D. R., Pym, A. S., Galpin, S., Foxall, R., Stainsby, C., Clarke, J. R., . . . Weber, J. N. (1999). The Rabbit Study: Ritonavir and Saquinavir in Combination in Saquinavir-Experienced and Previously Untreated Patients. AIDS Research and Human Retroviruses, 15(13), 1181-1189. doi:10.1089/088922299310278
Intracellular Activation of 2',3'-Dideoxyinosine and Drug Interactions in Vitro
Kewn, S., Hoggard, P. G., Henry-Mowatt, J. S., Veal, G. J., Sales, S. D., Barry, M. G., & Back, D. J. (1999). Intracellular Activation of 2',3'-Dideoxyinosine and Drug Interactions in Vitro. AIDS Research and Human Retroviruses, 15(9), 793-802. doi:10.1089/088922299310692
Poor penetration of the male genital tract by HIV-1 protease inhibitors
Taylor, S., Back, D. J., Workman, J., Drake, S. M., White, D. J., Choudhury, B., . . . Pillay, D. (1999). Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS, 13(7), 859. doi:10.1097/00002030-199905070-00017
Preclinical and<i>in vitro</i>assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions
McKILLOP, D., BACK, D. J., McCORMICK, A. D., EVANS, J. A., & TJIA, J. (1999). Preclinical and<i>in vitro</i>assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions. Xenobiotica, 29(4), 395-408. doi:10.1080/004982599238579
Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection
Barry, M., Mulcahy, F., Merry, C., Gibbons, S., & Back, D. (1999). Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection. Clinical Pharmacokinetics, 36(4), 289-304. doi:10.2165/00003088-199936040-00004
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients
Merry, C., Barry, M. G., Ryan, M., Tjia, J. F., Hennessy, M., Eagling, V. A., . . . Back, D. J. (1999). Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS, 13(15), 101-107. doi:10.1097/00002030-199910220-00001
The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation
Gill, H. J., Tjia, J. F., Kitteringham, N. R., Pirmohamed, M., Back, D. J., & Park, B. K. (1999). The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics, 9(1), 43-54. doi:10.1097/00008571-199902000-00007
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
Moore, K. H. P., Barrett, J. E., Shaw, S., Pakes, G. E., Churchus, R., Kapoor, A., . . . Back, D. (1999). The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS, 13(16), 2239-2250. doi:10.1097/00002030-199911120-00006
1998
Nelfinavir and nevirapine interaction?
Mulcahy, F., Barry, M., Merry, C., & Back, D. (1998). Nelfinavir and nevirapine interaction?. AIDS, 12(17), 2361.
The Role of CYP2C in the In Vitro Bioactivation of the Contraceptive Steroid Desogestrel
Gentile, D. M., Verhoeven, C. H. J., Shimada, T., & Back, D. J. (1998). The Role of CYP2C in the In Vitro Bioactivation of the Contraceptive Steroid Desogestrel. The Journal of Pharmacology and Experimental Therapeutics, 287(3), 975-982. doi:10.1016/s0022-3565(24)37890-5
Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.
Churchill, D. R., Pym, A. S., Babiker, A. G., Back, D. J., & Weber, J. N. (1998). Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.. British Journal of Clinical Pharmacology, 46(5), 518-519.
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Tjia, J. F., Halifax, K. L., . . . Back, D. J. (1998). The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS, 12(10), 1163-1167. doi:10.1097/00002030-199810000-00008
Letter to the Editors
Letter to the Editors (1998). British Journal of Clinical Pharmacology, 45(5), 501-502. doi:10.1046/j.1365-2125.1998.00714.x
Antiretroviral therapy for patients with HIV disease
Barry, M., Mulcahy, F., & Back, D. J. (1998). Antiretroviral therapy for patients with HIV disease. British Journal of Clinical Pharmacology, 45(3), 221-228. doi:10.1046/j.1365-2125.1998.00673.x
Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients.
Merry, C., Barry, M. G., Mulcahy, F., Tjia, J. F., Halifax, K. L., Heavey, J., . . . Back, D. J. (1998). Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients.. AIDS, 12(3), 325-327.
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
Eagling, V. A., Tjia, J. F., & Back, D. J. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45(2), 107-114. doi:10.1046/j.1365-2125.1998.00679.x
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro
Hoggard, P. G., Manion, V., Barry, M. G., & Back, D. J. (1998). Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro. British Journal of Clinical Pharmacology, 45(2), 164-167. doi:10.1046/j.1365-2125.1998.00660.x
Editorial
Editorial (1998). British Journal of Clinical Pharmacology, 45(2), 93. doi:10.1046/j.1365-2125.1998.00675.x
Effect of Ribavirin on Zidovudine Efficacy and Toxicity <i>in Vitro</i> : A Concentration-Dependent Interaction
SIM, S. M., HOGGARD, P. G., SALES, S. D., PHIBOONBANAKIT, D., HART, C. A., & BACK, D. J. (1998). Effect of Ribavirin on Zidovudine Efficacy and Toxicity <i>in Vitro</i> : A Concentration-Dependent Interaction. AIDS Research and Human Retroviruses, 14(18), 1661-1667. doi:10.1089/aid.1998.14.1661
1997
Lack of effect of sibutramine an the efficacy of oral contraceptive steroids in healthy women
Back, D. J., Fearn, R., Oliver, S., Stott, D. A., & Wynne, R. D. (1997). Lack of effect of sibutramine an the efficacy of oral contraceptive steroids in healthy women. International Journal of Pharmaceutical Medicine, 11(2), 71-76.
In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3a4 and CYP17 (17,20 LYASE) and molecular modelling studies
Tomlinson, E. S., Lewis, D. F. V., Maggs, J. L., Kroemer, H. K., Park, B. K., & Back, D. J. (1997). In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3a4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochemical Pharmacology, 54(5), 605-611. doi:10.1016/s0006-2952(97)00166-4
Lamivudine (3TC) phosphorylation and drug interactions in vitro
Kewn, S., Veal, G. J., Hoggard, P. G., Barry, M. G., & Back, D. J. (1997). Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochemical Pharmacology, 54(5), 589-595. doi:10.1016/s0006-2952(97)00189-5
Dexamethasone metabolism in vitro: Species differences
Tomlinson, E. S., Maggs, J. L., Park, B. K., & Back, D. J. (1997). Dexamethasone metabolism in vitro: Species differences. The Journal of Steroid Biochemistry and Molecular Biology, 62(4), 345-352. doi:10.1016/s0960-0760(97)00038-1
Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
Merry, C., Mulcahy, F., Barry, M., Gibbons, S., & Back, D. (1997). Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.. AIDS, 11(2), 268-269.
<i>In Vitro</i> Screening of Nucleoside Analog Combinations for Potential Use in Anti-HIV Therapy
VEAL, G. J., BARRY, M. G., KHOO, S. H., & BACK, D. J. (1997). <i>In Vitro</i> Screening of Nucleoside Analog Combinations for Potential Use in Anti-HIV Therapy. AIDS Research and Human Retroviruses, 13(6), 481-484. doi:10.1089/aid.1997.13.481
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
Eagling, V. A., Back, D. J., & Barry, M. G. (1997). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology, 44(2), 190-194. doi:10.1046/j.1365-2125.1997.00644.x
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro
Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrobial Agents and Chemotherapy, 41(6), 1231-1236. doi:10.1128/aac.41.6.1231
Erratum: 'Lack of effect of sibutramine on the efficacy of oral contraceptive steroids in healthy women' (International Journal of Pharmaceutical Medicine (1997) 11 (71-76))
Back, D. J., Fearn, R., Stott, D. A., & Wynne, R. D. (1997). Erratum: 'Lack of effect of sibutramine on the efficacy of oral contraceptive steroids in healthy women' (International Journal of Pharmaceutical Medicine (1997) 11 (71-76)). International Journal of Pharmaceutical Medicine, 11(4), 244.
Protease Inhibitors in Patients with HIV Disease
Barry, M., Gibbons, S., Back, D., & Mulcahy, F. (1997). Protease Inhibitors in Patients with HIV Disease. Clinical Pharmacokinetics, 32(3), 194-209. doi:10.2165/00003088-199732030-00003
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
Merry, C., Barry, M. G., Mulcahy, F., Halifax, K. L., & Back, D. J. (1997). Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS, 11(15), F117-F120. doi:10.1097/00002030-199715000-00001
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J. F., . . . Back, D. J. (1997). Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS, 11(4), F29-F33. doi:10.1097/00002030-199704000-00001
1996
Theophylline metabolism in human liver microsomes: inhibition studies.
Tjia, J. F., Colbert, J., & Back, D. J. (1996). Theophylline metabolism in human liver microsomes: inhibition studies.. The Journal of Pharmacology and Experimental Therapeutics, 276(3), 912-917. doi:10.1016/s0022-3565(25)12414-2
Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation.
Gentile, D. M., Tomlinson, E. S., Maggs, J. L., Park, B. K., & Back, D. J. (1996). Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation.. The Journal of Pharmacology and Experimental Therapeutics, 277(1), 105-112. doi:10.1016/s0022-3565(25)12795-x
Dexamethasone metabolism in vitro: Species differences in 6-hydroxylation
Tomlinson, E. S., Maggs, J. L., Park, B. K., & Back, D. J. (1996). Dexamethasone metabolism in vitro: Species differences in 6-hydroxylation. British Journal of Clinical Pharmacology, 41(5).
How important is the pharmacokinetics issue for the pharmacodynamic diversity of oral contraceptives?
Back, D. J. (1996). How important is the pharmacokinetics issue for the pharmacodynamic diversity of oral contraceptives?. Gynecological Endocrinology, 10(sup2), 31-34. doi:10.3109/09513599609045624
Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease
Kapembwa, M. S., Fleming, S. C., Orr, M., Wells, C., Bland, M., Back, D., & Griffin, G. E. (1996). Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. AIDS, 10(13), 1509-1514. doi:10.1097/00002030-199611000-00008
Improved tolerability of ritonavir derived from pharmacokinetic principles
Improved tolerability of ritonavir derived from pharmacokinetic principles (1996). British Journal of Clinical Pharmacology, 42(6), 787. doi:10.1046/j.1365-2125.1996.d01-3339.x
Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation
Veal, G. J., Hoggard, P. G., Barry, M. G., Khoo, S., & Back, D. J. (1996). Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS, 10(5), 546-548. doi:10.1097/00002030-199605000-00016
Intracellular Metabolism of Zidovudine and Stavudine in Combination
Hoggard, P., Khoo, S., Barry, M., & Back, D. (1996). Intracellular Metabolism of Zidovudine and Stavudine in Combination. Journal of Infectious Diseases, 174(3), 671-672. doi:10.1093/infdis/174.3.671
Lack of association between schizophrenia and theCYPZD6 gene polymorphisms
Pirmohamed, M., Wild, M. J., Kitteringham, N. R., O'Brien, K., Buchan, I. E., Back, D. J., & Park, B. K. (1996). Lack of association between schizophrenia and theCYPZD6 gene polymorphisms. American Journal of Medical Genetics, 67(2), 236-237. doi:10.1002/ajmg.1320670205
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites
Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G. L., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. doi:10.1097/00002030-199610000-00008
1995
Paracetamol disposition in Thai patients during and after treatment of falciparum malaria
Ismail, S., Back, D. J., Edwards, G., Na Bangchang, K., & Karbwang, J. (1995). Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. European Journal of Clinical Pharmacology, 48(1). doi:10.1007/bf00202175
Drug interactions with zidovudine phosphorylation in vitro
Hoggard, P. G., Veal, G. J., Wild, M. J., Barry, M. G., & Back, D. J. (1995). Drug interactions with zidovudine phosphorylation in vitro. Antimicrobial Agents and Chemotherapy, 39(6), 1376-1378. doi:10.1128/aac.39.6.1376
Effect of Azoles on the Glucuronidation of Zidovudine by Human Liver UDP-Glucuronosyltransferase
Asgari, M., & Back, D. J. (1995). Effect of Azoles on the Glucuronidation of Zidovudine by Human Liver UDP-Glucuronosyltransferase. Journal of Infectious Diseases, 172(6), 1634-1635. doi:10.1093/infdis/172.6.1634
Influence of high doses of vitamin C on the bioavailability and the serum protein binding of levonorgestrel in women using a combination oral contraceptive
Kuhnz, W., Louton, T., Hümpel, M., Back, D. J., & Zaman, N. M. (1995). Influence of high doses of vitamin C on the bioavailability and the serum protein binding of levonorgestrel in women using a combination oral contraceptive. Contraception, 51(2), 111-116. doi:10.1016/0010-7824(94)00016-p
Metabolism of zidovudine
Veal, G. J., & Back, D. J. (1995). Metabolism of zidovudine. General Pharmacology: The Vascular System, 26(7), 1469-1475. doi:10.1016/0306-3623(95)00047-x
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
Gibb, D., Barry, M., Ormesher, S., Nokes, L., Seefried, M., Giaquinto, C., & Back, D. (1995). Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.. British Journal of Clinical Pharmacology, 39(5), 527-530. doi:10.1111/j.1365-2125.1995.tb04490.x
Zalcitabine (ddC) Phosphorylation and Drug Interactions
Veal, G. J., Barry, M. G., & Back, D. J. (1995). Zalcitabine (ddC) Phosphorylation and Drug Interactions. Antiviral Chemistry and Chemotherapy, 6(6), 379-384. doi:10.1177/095632029500600605
Zidovudine therapy in HIV infection: which patients should be treated and when.
Barry, M. G., Back, D. J., & Breckenridge, A. M. (1995). Zidovudine therapy in HIV infection: which patients should be treated and when.. British Journal of Clinical Pharmacology, 40(2), 107-110. doi:10.1111/j.1365-2125.1995.tb05765.x
1994
An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers
Mengel, H. B., Houston, A., & Back, D. J. (1994). An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. Journal of Pharmaceutical Medicine, 4(3), 141-150.
The metabolism of zidovudine by human liver microsomes in vitro: Formation of 3′-amino-3′-deoxythymidine
Eagling, V. A., Howe, J. L., Barry, M. J., & Back, D. J. (1994). The metabolism of zidovudine by human liver microsomes in vitro: Formation of 3′-amino-3′-deoxythymidine. Biochemical Pharmacology, 48(2), 267-276. doi:10.1016/0006-2952(94)90097-3
Pharmacokinetics of mefloquine alone or in combination with artesunate.
Karbwang, J., Na Bangchang, K., Thanavibul, A., Back, D. J., Bunnag, D., & Harinasuta, T. (1994). Pharmacokinetics of mefloquine alone or in combination with artesunate.. Bulletin of the World Health Organization, 72(1), 83-87.
Effect of malaria infection on the pharmacokinetics of paracetamol in rat
Ismail, S., Kokwaro, G. O., Back, D. J., & Edwards, G. (1994). Effect of malaria infection on the pharmacokinetics of paracetamol in rat. Xenobiotica, 24(6), 527-533. doi:10.3109/00498259409043255
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.
Veal, G. J., Wild, M. J., Barry, M. G., & Back, D. J. (1994). Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.. British Journal of Clinical Pharmacology, 38(4), 323-328. doi:10.1111/j.1365-2125.1994.tb04361.x
Pharmacokinetics of Zidovudine in Children with Symptomatic HIV Infection
Barry, M., Howe, J. L., Back, D. J., Han, I., & Gibb, D. (1994). Pharmacokinetics of Zidovudine in Children with Symptomatic HIV Infection. Drug Investigation, 7(3), 143-147. doi:10.1007/bf03258466
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
Barry, M., Howe, J. L., Ormesher, S., Back, D. J., Breckenridge, A. M., Bergin, C., . . . Nye, F. (1994). Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.. British Journal of Clinical Pharmacology, 37(5), 421-426. doi:10.1111/j.1365-2125.1994.tb05708.x
Zidovudine pharmacokinetics in zidovudine‐induced bone marrow toxicity.
Barry, M., Howe, J. L., Back, D. J., Swart, A. M., Breckenridge, A. M., Weller, I. V., . . . Nye, F. (1994). Zidovudine pharmacokinetics in zidovudine‐induced bone marrow toxicity.. British Journal of Clinical Pharmacology, 37(1), 7-12. doi:10.1111/j.1365-2125.1994.tb04231.x
Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers
Barry, M., Wild, M., Veal, G., Back, D., Breckenridge, A., Fox, R., . . . Timmins, D. (1994). Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS, 8(8), F1-1024. doi:10.1097/00002030-199408000-00002
1993
Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives
Back, D. J., Power, J., Winkler, U., Schindler, A. E., Daume, E., Simon, A., . . . Hammerstein, J. (1993). Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. Advances in Contraception, 9(4), 319-330. doi:10.1007/bf01983210
Effect of chlormethiazole on hepatic monooxygenases activity in vivo
M�nig, H., Back, D. J., Heidemann, H. T., Ohnhaus, E. E., Brockmann, B., & Schulte, H. M. (1993). Effect of chlormethiazole on hepatic monooxygenases activity in vivo. European Journal of Clinical Pharmacology, 44(2), 203-204. doi:10.1007/bf00315482
Absence of an effect of high vitamin C dosage on the systemic availability of ethinyl estradiol in women using a combination oral contraceptive
Zamah, N. M., Hümpel, M., Kuhnz, W., Louton, T., Rafferty, J., & Back, D. J. (1993). Absence of an effect of high vitamin C dosage on the systemic availability of ethinyl estradiol in women using a combination oral contraceptive. Contraception, 48(4), 377-391. doi:10.1016/0010-7824(93)90083-j
Cortisol metabolism by human liver in vitro—IV. Metabolism of 9α-fluorocortisol by human liver microsomes and cytosol
Abel, S. M., Back, D. J., Maggs, J. L., & Park, B. K. (1993). Cortisol metabolism by human liver in vitro—IV. Metabolism of 9α-fluorocortisol by human liver microsomes and cytosol. The Journal of Steroid Biochemistry and Molecular Biology, 46(6), 833-839. doi:10.1016/0960-0760(93)90326-r
Cortisol metabolism in vitro—II. Species difference
Abel, S. M., Back, D. J., Maggs, J. L., & Park, B. K. (1993). Cortisol metabolism in vitro—II. Species difference. The Journal of Steroid Biochemistry and Molecular Biology, 45(5), 445-453. doi:10.1016/0960-0760(93)90013-m
Cortisol metabolism in vitro—III. Inhibition of microsomal 6β—hydroxylase and cytosolic 4-ene-reductase
Abel, S. M., & Back, D. J. (1993). Cortisol metabolism in vitro—III. Inhibition of microsomal 6β—hydroxylase and cytosolic 4-ene-reductase. The Journal of Steroid Biochemistry and Molecular Biology, 46(6), 827-832. doi:10.1016/0960-0760(93)90325-q
Effect of etretinate on cyclosporin metabolism in vitro
WEBBBR, I. R., & BACK, D. J. (1993). Effect of etretinate on cyclosporin metabolism in vitro. British Journal of Dermatology, 128(1), 42-44. doi:10.1111/j.1365-2133.1993.tb00145.x
Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6β-hydroxycortisol
Hammerstein, J., Daume, E., Simon, A., Winkler, U. H., Schindler, A. E., Back, D. J., . . . Neiss, A. (1993). Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6β-hydroxycortisol. Contraception, 47(3), 263-281. doi:10.1016/0010-7824(93)90043-7
Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications [letter]
Barry, M., Back, D., Ormesher, S., Beeching, N., & Nye, F. (1993). Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications [letter]. British Journal of Clinical Pharmacology, 36(1), 87-88. doi:10.1111/j.1365-2125.1993.tb05899.x
Metabolism of gestodene in human liver cytosol and microsomes in vitro
Ward, S., & Back, D. J. (1993). Metabolism of gestodene in human liver cytosol and microsomes in vitro. The Journal of Steroid Biochemistry and Molecular Biology, 46(2), 235-243. doi:10.1016/0960-0760(93)90299-c
Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro
Wild, M. J., Rudland, P. S., & Back, D. J. (1993). Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro. The Journal of Steroid Biochemistry and Molecular Biology, 45(5), 407-420. doi:10.1016/0960-0760(93)90010-t
Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay.
Kuhnz, W., Louton, T., Back, D. J., & Michaelis, K. (1993). Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay.. Drug Research, 43(1), 16-21.
The effects of indomethacin and naproxen on zidovudine pharmacokinetics.
Barry, M., Howe, J., Back, D., Breckenridge, A., Brettle, R., Mitchell, R., . . . Nye, F. J. (1993). The effects of indomethacin and naproxen on zidovudine pharmacokinetics.. British Journal of Clinical Pharmacology, 36(1), 82-85. doi:10.1111/j.1365-2125.1993.tb05898.x
1992
The effect of malaria infection on 3'-azido-3'-deoxythymidine and paracetamol glucuronidation in rat liver microsomes
Ismail, S., Back, D. J., & Edwards, G. (1992). The effect of malaria infection on 3'-azido-3'-deoxythymidine and paracetamol glucuronidation in rat liver microsomes. Biochemical Pharmacology, 44(9), 1879-1882. doi:10.1016/0006-2952(92)90084-v
Effect of tetracycline on mefloquine pharmacokinetics in Thai males
Karbwang, J., Na Bangchang, K., Back, D. J., Bunnag, D., & Rooney, W. (1992). Effect of tetracycline on mefloquine pharmacokinetics in Thai males. European Journal of Clinical Pharmacology, 43(5), 567-569. doi:10.1007/bf02285105
Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs
Bangchang, K. N., Karbwang, J., & Back, D. J. (1992). Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochemical Pharmacology, 44(3), 587-590. doi:10.1016/0006-2952(92)90453-p
Loss of taste and terbinafine
Back, D. (1992). Loss of taste and terbinafine. The Lancet, 340(8813), 252. doi:10.1016/0140-6736(92)90528-b
Mefloquine metabolism by human liver microsomes
Bangchang, K. N., Karbwang, J., & Back, D. J. (1992). Mefloquine metabolism by human liver microsomes. Biochemical Pharmacology, 43(9), 1957-1961. doi:10.1016/0006-2952(92)90638-y
Pharmacokinetics of mefloquine in the presence of primaquine
Karbwang, J., Bangchang, K. N., Thanavibul, A., Back, D. J., & Bunnag, D. (1992). Pharmacokinetics of mefloquine in the presence of primaquine. European Journal of Clinical Pharmacology, 42(5), 559-560. doi:10.1007/bf00314870
In vitro inhibition studies of the glucuronidation of 3′-azido-3′-deoxythymidine catalysed by human liver UDP-glucuronosyl transferase
Macleod, R., Eagling, V. A., Sim, S. M., & Back, D. J. (1992). In vitro inhibition studies of the glucuronidation of 3′-azido-3′-deoxythymidine catalysed by human liver UDP-glucuronosyl transferase. Biochemical Pharmacology, 43(2), 382-386. doi:10.1016/0006-2952(92)90303-z
Azoles, a48 llylamines and drug metabolism
BACK, D. J., TJIA, J. F., & ABEL, S. M. (1992). Azoles, a48 llylamines and drug metabolism. British Journal of Dermatology, 126(s39), 14-18. doi:10.1111/j.1365-2133.1992.tb00003.x
Bacterial and hepatic metabolism of zidovudine (AZT) to the toxic catabolite 3'-amino-3'-deoxythymidine (AMT)
Howe, J. L., Back, D. J., Eagling, V., & Hart, C. A. (1992). Bacterial and hepatic metabolism of zidovudine (AZT) to the toxic catabolite 3'-amino-3'-deoxythymidine (AMT). In British Journal of Clinical Pharmacology Vol. 34 (pp. 165).
Cortisol metabolism by human liver in vitro
Abel, S. M., Maggs, J. L., Back, D. J., Newby, S., Colbert, J., & Park, B. K. (1992). Cortisol metabolism by human liver in vitro. In British Journal of Clinical Pharmacology Vol. 33 (pp. 231).
Cortisol metabolism by human liver in vitro—I. Metabolite identification and inter-individual variability
Abel, S. M., Maggs, J. L., Back, D. J., & Park, B. K. (1992). Cortisol metabolism by human liver in vitro—I. Metabolite identification and inter-individual variability. The Journal of Steroid Biochemistry and Molecular Biology, 43(7), 713-719. doi:10.1016/0960-0760(92)90297-v
Cyclosporin metabolism by human gastrointestinal mucosal microsomes.
Webber, I. R., Peters, W. H., & Back, D. J. (1992). Cyclosporin metabolism by human gastrointestinal mucosal microsomes.. British Journal of Clinical Pharmacology, 33(6), 661-664. doi:10.1111/j.1365-2125.1992.tb04098.x
Extrahepatic metabolism of zidovudine.
Howe, J. L., Back, D. J., & Colbert, J. (1992). Extrahepatic metabolism of zidovudine.. British Journal of Clinical Pharmacology, 33(2), 190-192. doi:10.1111/j.1365-2125.1992.tb04024.x
Metabolism of 2′,3′‐dideoxyinosine (ddI) in human blood.
Back, D. J., Ormesher, S., Tjia, J. F., & Macleod, R. (1992). Metabolism of 2′,3′‐dideoxyinosine (ddI) in human blood.. British Journal of Clinical Pharmacology, 33(3), 319-322. doi:10.1111/j.1365-2125.1992.tb04043.x
Metabolism of contraceptive steroids by human endometrial tissue and an endometrial cancer cell-line (HEC-1A) in vitro
Wild, M. J., Back, D. J., & Rudland, P. S. (1992). Metabolism of contraceptive steroids by human endometrial tissue and an endometrial cancer cell-line (HEC-1A) in vitro. In British Journal of Clinical Pharmacology Vol. 33 (pp. 216).
Metabolism of the oral contraceptive steroid gestodene by human liver in vitro
Ward, S., & Back, D. J. (1992). Metabolism of the oral contraceptive steroid gestodene by human liver in vitro. In British Journal of Clinical Pharmacology Vol. 34.
Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
Kuhnz, W., al-Yacoub, G., Power, J., Ormesher, S. E., Back, D. J., & Jütting, G. (1992). Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.. Drug Research, 42(9), 1142-1146.
Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
Kuhnz, W., Schütt, B., Power, J., & Back, D. J. (1992). Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.. Drug Research, 42(9), 1139-1141.
Relative expression of cytochrome <i>P</i>450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics
Forrester, L. M., Henderson, C. J., Glancey, M. J., Back, D. J., Park, B. K., Ball, S. E., . . . Wolf, C. R. (1992). Relative expression of cytochrome <i>P</i>450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281(2), 359-368. doi:10.1042/bj2810359
Species differences in the in vitro metabolism of cortisol
Abel, S. M., Back, D. J., Maggs, J. L., & Park, B. K. (1992). Species differences in the in vitro metabolism of cortisol. In British Journal of Clinical Pharmacology Vol. 34 (pp. 163).
The in‐vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease
GRIMMER, S. F. M., BACK, D. J., ORME, M. L., TJIA, J. F., GILMORE, I. T., & ELLIS, A. (1992). The in‐vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. Alimentary Pharmacology & Therapeutics, 6(1), 79-85. doi:10.1111/j.1365-2036.1992.tb00547.x
1991
Effect of ampicillin on mefloquine pharmacokinetics in thai males
Karbwang, J., Na Bangchang, K., Back, D. J., & Bunnag, D. (1991). Effect of ampicillin on mefloquine pharmacokinetics in thai males. European Journal of Clinical Pharmacology, 40(6), 631-633. doi:10.1007/bf00279985
Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.
Back, D. J., & Tjia, J. F. (1991). Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.. British Journal of Clinical Pharmacology, 32(5), 624-626. doi:10.1111/j.1365-2125.1991.tb03963.x
Concentration of Ethinyl Estradiol in the Serum of 31 Young Women following a Treatment Period of 3 Months with Two Low-Dose Oral Contraceptives in an Intraindividual Cross-Over Design
Kuhnz, W., Back, D., Power, J., Schütt, B., & Louton, T. (2008). Concentration of Ethinyl Estradiol in the Serum of 31 Young Women following a Treatment Period of 3 Months with Two Low-Dose Oral Contraceptives in an Intraindividual Cross-Over Design. Hormone Research, 63-69. doi:10.1159/000182110
Cyclosporin metabolism by the gastrointestinal mucosa.
Tjia, J. F., Webber, I. R., & Back, D. J. (1991). Cyclosporin metabolism by the gastrointestinal mucosa.. British Journal of Clinical Pharmacology, 31(3), 344-346. doi:10.1111/j.1365-2125.1991.tb05540.x
Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes
Back, D. J., Houlgrave, R., Tjia, J. F., Ward, S., & L'e. Orme, M. (1991). Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. The Journal of Steroid Biochemistry and Molecular Biology, 38(2), 219-225. doi:10.1016/0960-0760(91)90129-s
Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro
Madden, S., & Back, D. J. (1991). Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. The Journal of Steroid Biochemistry and Molecular Biology, 38(4), 497-503. doi:10.1016/0960-0760(91)90338-6
Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture
Wild, M. J., Rudland, P. S., & Back, D. J. (1991). Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture. The Journal of Steroid Biochemistry and Molecular Biology, 39(4), 535-543. doi:10.1016/0960-0760(91)90248-4
Oral contraceptive steroids —pharmacological issues of interest to the prescribing physician
Orme, M., & Back, D. J. (1991). Oral contraceptive steroids —pharmacological issues of interest to the prescribing physician. Advances in Contraception, 7(4), 325-331. doi:10.1007/bf02340178
The effect of metoclopramide on mefloquine pharmacokinetics [letter]
Bangchang, N. K., Karbwang, J., Bunnag, D., Harinasuta, T., & Back, D. J. (1991). The effect of metoclopramide on mefloquine pharmacokinetics [letter]. British Journal of Clinical Pharmacology, 32(5), 640-641. doi:10.1111/j.1365-2125.1991.tb03969.x
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.
Sim, S. M., Back, D. J., & Breckenridge, A. M. (1991). The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.. British Journal of Clinical Pharmacology, 32(1), 17-21. doi:10.1111/j.1365-2125.1991.tb05607.x
The interaction between clarithromycin and combined oral-contraceptive steroids
Back, D. J., Tjia, J., Martin, C., Millar, E., Salmon, P., & Orme, M. (1991). The interaction between clarithromycin and combined oral-contraceptive steroids. Journal of Pharmaceutical Medicine, 1(2), 81-87.
The lack of interaction between clarithromycin and oral contraceptive steroids
Orme, M., Back, D. J., Tjia, J., Martin, C., Millar, E., & Salmon, P. (1991). The lack of interaction between clarithromycin and oral contraceptive steroids. In British Journal of Clinical Pharmacology Vol. 31 (pp. 229).
The lack of interaction between temafloxacin and combined oral contraceptive steroids
Back, D. J., Tjia, J., Martin, C., Millar, E., Mant, T., Morrison, P., & Orme, M. (1991). The lack of interaction between temafloxacin and combined oral contraceptive steroids. Contraception, 43(4), 317-323. doi:10.1016/0010-7824(91)90070-v
The lack of interaction between temafloxacin and oral contraceptive steroids
Orme, M., Back, D. J., Tjia, J., Martin, C., Millar, E., Mant, T., & Morrison, P. (1991). The lack of interaction between temafloxacin and oral contraceptive steroids. In British Journal of Clinical Pharmacology Vol. 31 (pp. 228).
The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel
Orme, M., Back, D. J., Ward, S., & Green, S. (1991). The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception, 43(4), 305-316. doi:10.1016/0010-7824(91)90069-r
Unintended pregnancies and contraceptive use.
Unintended pregnancies and contraceptive use. (1991). BMJ, 302(6779), 789-790. doi:10.1136/bmj.302.6779.789-b
1990
Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.
Karbwang, J., Back, D. J., Bunnag, D., & Breckenridge, A. M. (1990). Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.. Bulletin of the World Health Organization, 68(5), 633-638.
Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymes
Back, D., & Tija, J. (1990). Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymes. Journal of Dermatological Treatment, 1(sup2), 11-13. doi:10.3109/09546639009089023
Differences in the cytochrome <i>P</i>-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol. Relative activities of rat and human liver enzymes
Ball, S. E., Forrester, L. M., Wolf, C. R., & Back, D. J. (1990). Differences in the cytochrome <i>P</i>-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol. Relative activities of rat and human liver enzymes. Biochemical Journal, 267(1), 221-226. doi:10.1042/bj2670221
Factors affecting the enterohepatic circulation of oral contraceptive steroids
Orme, M. L., & Back, D. J. (1990). Factors affecting the enterohepatic circulation of oral contraceptive steroids. American Journal of Obstetrics and Gynecology, 163(6), 2146-2152. doi:10.1016/0002-9378(90)90555-l
Gastrointestinal metabolism of contraceptive steroids
Back, D. J., Madden, S., & Orme, M. L. (1990). Gastrointestinal metabolism of contraceptive steroids. American Journal of Obstetrics and Gynecology, 163(6), 2138-2145. doi:10.1016/0002-9378(90)90554-k
Metabolism of the contraceptive steroid desogestrel by human liver in vitro
Madden, S., Back, D. J., & Orme, M. L. (1990). Metabolism of the contraceptive steroid desogestrel by human liver in vitro. Journal of Steroid Biochemistry, 35(2), 281-288. doi:10.1016/0022-4731(90)90285-z
Pharmacokinetic Drug Interactions with Oral Contraceptives
Back, D. J., & Orme, M. L. (1990). Pharmacokinetic Drug Interactions with Oral Contraceptives. Clinical Pharmacokinetics, 18(6), 472-484. doi:10.2165/00003088-199018060-00004
The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.
Crawford, P., Chadwick, D. J., Martin, C., Tjia, J., Back, D. J., & Orme, M. (1990). The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.. British Journal of Clinical Pharmacology, 30(6), 892-896. doi:10.1111/j.1365-2125.1990.tb05457.x
The interaction of phenytoin and carbamazepine with oral contraceptive steroids
Orme, M., Back, D. J., Chadwick, D. J., Crawford, P., Martin, C., & Tjia, J. (1990). The interaction of phenytoin and carbamazepine with oral contraceptive steroids. In European Journal of Pharmacology Vol. 183 (pp. 1029-1030). Elsevier BV. doi:10.1016/0014-2999(90)92884-l
1989
INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY OF HUMAN-LIVER MICROSOMES BY CIMETIDINE INVITRO - EFFECT OF PREINCUBATION
WILD, M. J., & BACK, D. J. (1989). INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY OF HUMAN-LIVER MICROSOMES BY CIMETIDINE INVITRO - EFFECT OF PREINCUBATION. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 28(6), P744-P745. Retrieved from https://www.webofscience.com/
CYCLOSPORIN METABOLITES AND NEUROTOXICITY
Trull, A. K., Tan, K. K. C., Roberts, N. B., Tjia, J. F., & Back, D. J. (1989). CYCLOSPORIN METABOLITES AND NEUROTOXICITY. The Lancet, 334(8660), 448. doi:10.1016/s0140-6736(89)90626-0
Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.
Tjia, J. F., Back, D. J., & Breckenridge, A. M. (1989). Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.. British Journal of Clinical Pharmacology, 28(3), 362-365. doi:10.1111/j.1365-2125.1989.tb05439.x
Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro.
Back, D. J., Stevenson, P., & Tjia, J. F. (1989). Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro.. British Journal of Clinical Pharmacology, 28(2), 166-170. doi:10.1111/j.1365-2125.1989.tb05410.x
Genetic factors influencing the metabolism of tolbutamide
Back, D. J., & Orme, M. L. (1989). Genetic factors influencing the metabolism of tolbutamide. Pharmacology & Therapeutics, 44(2), 147-155. doi:10.1016/0163-7258(89)90064-8
Interindividual variation in the metabolism of ethynylestradiol
Orme, M. L., Back, D. J., & Ball, S. (1989). Interindividual variation in the metabolism of ethynylestradiol. Pharmacology & Therapeutics, 43(2), 251-260. doi:10.1016/0163-7258(89)90121-6
Intestinal metabolism of contraceptive steroids in man
Back, D. J., Orme 'E., M. L., & Rogers, S. M. (1989). Intestinal metabolism of contraceptive steroids in man. Progress in Pharmacology and Clinical Pharmacology, 7(2), 289-297.
METABOLISM OF THE CONTRACEPTIVE STEROID NORGESTIMATE BY HUMAN GUT AND LIVER INVITRO
MADDEN, S., & BACK, D. J. (1989). METABOLISM OF THE CONTRACEPTIVE STEROID NORGESTIMATE BY HUMAN GUT AND LIVER INVITRO. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 28(6), P743-P744. Retrieved from https://www.webofscience.com/
Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.
Madden, S., Back, D. J., Martin, C. A., & Orme, M. L. (1989). Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.. British Journal of Clinical Pharmacology, 27(3), 295-299. doi:10.1111/j.1365-2125.1989.tb05368.x
The use of Ussing chambers for the study of intestinal metabolism in vitro
Rogers, S. M., & Back, D. J. (1989). The use of Ussing chambers for the study of intestinal metabolism in vitro. Progress in Pharmacology and Clinical Pharmacology, 7(2), 43-53.
1988
Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women.
Karbwang, J., Looareesuwan, S., Back, D. J., Migasana, S., Bunnag, D., & Breckenridge, A. M. (1988). Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women.. Bulletin of the World Health Organization, 66(6), 763-767.
Sulphation and glucuronidation of paracetamol in human liver: assay conditions
Pacifici, G. M., Back, D. J., & Orme, M. L. (1988). Sulphation and glucuronidation of paracetamol in human liver: assay conditions. Biochemical Pharmacology, 37(22), 4405-4407. doi:10.1016/0006-2952(88)90624-7
A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria
Karbwang, J., Back, D. J., Bunnag, D., & Breckenridge, A. M. (1988). A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. European Journal of Clinical Pharmacology, 35(6), 677-680. doi:10.1007/bf00637607
Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide
Back, D. J., Tjia, J., M�nig, H., Ohnhaus, E. E., & Park, B. K. (1988). Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. European Journal of Clinical Pharmacology, 34(2), 157-163. doi:10.1007/bf00614553
CHARACTERIZATION AND INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY IN HUMAN-LIVER MICROSOMES
BALL, S., BACK, D. J., & ORME, M. L. E. (1988). CHARACTERIZATION AND INHIBITION OF ESTROGEN 2-HYDROXYLASE ACTIVITY IN HUMAN-LIVER MICROSOMES. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 25(5), P643-P644. Retrieved from https://www.webofscience.com/
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive‐drug interactions with anticonvulsants and antibiotics.
Back, D. J., Grimmer, S. F., Orme, M. L., Proudlove, C., Mann, R. D., & Breckenridge, A. M. (1988). Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive‐drug interactions with anticonvulsants and antibiotics.. British Journal of Clinical Pharmacology, 25(5), 527-532. doi:10.1111/j.1365-2125.1988.tb03341.x
In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.
Back, D. J., Tjia, J. F., Karbwang, J., & Colbert, J. (1988). In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.. British Journal of Clinical Pharmacology, 26(1), 23-29. doi:10.1111/j.1365-2125.1988.tb03359.x
Inhibition of tolbutamide metabolism by antimalarial drugs.
Karbwang, J., Back, D. J., Bunnag, D., & Breckenridge, A. M. (1988). Inhibition of tolbutamide metabolism by antimalarial drugs.. The Southeast Asian Journal of Tropical Medicine and Public Health, 19(2), 235-241.
PRE-SYSTEMIC METABOLISM OF THE ORAL-CONTRACEPTIVE STEROID DESOGESTREL
BACK, D. J., MADDEN, S., & MARTIN, C. A. (1988). PRE-SYSTEMIC METABOLISM OF THE ORAL-CONTRACEPTIVE STEROID DESOGESTREL. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 25(5), P675-P676. Retrieved from https://www.webofscience.com/
Sulphation and glucuronidation of ethinyloestradiol in human liver In vitro
Pacifici, G. M., & Back, D. J. (1988). Sulphation and glucuronidation of ethinyloestradiol in human liver In vitro. Journal of Steroid Biochemistry, 31(3), 345-349. doi:10.1016/0022-4731(88)90360-3
1987
INHIBITION OF THEOPHYLLINE METABOLISM BY INTERFERON
Winstanley, P. A., Back, D. J., & Breckenridge, A. M. (1987). INHIBITION OF THEOPHYLLINE METABOLISM BY INTERFERON. The Lancet, 330(8571), 1340. doi:10.1016/s0140-6736(87)91240-2
Single dose primaquine has no effect on paracetamol clearance
Back, D. J., & Tjia, J. F. (1987). Single dose primaquine has no effect on paracetamol clearance. European Journal of Clinical Pharmacology, 32(2), 203-205. doi:10.1007/bf00542197
The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects
Karbwang, J., Bunnag, D., Breckenridge, A. M., & Back, D. J. (1987). The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. European Journal of Clinical Pharmacology, 32(2), 173-177. doi:10.1007/bf00542191
Comparative pharmacokinetics of levonqrgestrel and ethinyloestradiol following intravenous, oral and vaginal administration
Back, D. J., Grimmer, S. F. M., Rogers, S., Stevenson, P. J., & Orme, M. L. (1987). Comparative pharmacokinetics of levonqrgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. Contraception, 36(4), 471-479. doi:10.1016/0010-7824(87)90095-3
Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers.
Rogers, S. M., Back, D. J., & Orme, M. L. (1987). Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers.. British Journal of Clinical Pharmacology, 23(6), 727-734. doi:10.1111/j.1365-2125.1987.tb03108.x
Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol.
Rogers, S. M., Back, D. J., Stevenson, P. J., Grimmer, S. F., & Orme, M. L. (1987). Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol.. British Journal of Clinical Pharmacology, 23(6), 721-725. doi:10.1111/j.1365-2125.1987.tb03107.x
Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Stead, R. J., Grimmer, S. F., Rogers, S. M., Back, D. J., Orme, M. L., Hodson, M. E., & Batten, J. C. (1987). Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.. Thorax, 42(1), 59-64. doi:10.1136/thx.42.1.59
Plasma and whole blood mefloquine concentrations during treatment of chloroquine‐resistant falciparum malaria with the combination mefloquine‐sulphadoxine‐pyrimethamine.
Karbwang, J., Looareesuwan, S., Phillips, R. E., Wattanagoon, Y., Molyneux, M. E., Nagachinta, B., . . . Warrell, D. A. (1987). Plasma and whole blood mefloquine concentrations during treatment of chloroquine‐resistant falciparum malaria with the combination mefloquine‐sulphadoxine‐pyrimethamine.. British Journal of Clinical Pharmacology, 23(4), 477-481. doi:10.1111/j.1365-2125.1987.tb03079.x
Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel
Back, D. J., Grimmer, S. F. M., Shenoy, N., & Orme, M. L. E. (1987). Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception, 35(6), 619-626. doi:10.1016/s0010-7824(87)80021-5
Review: first‐pass metabolism by the gastrointestinal mucosa
BACK, D. J., & ROGERS, S. M. (1987). Review: first‐pass metabolism by the gastrointestinal mucosa. Alimentary Pharmacology & Therapeutics, 1(5), 339-357. doi:10.1111/j.1365-2036.1987.tb00634.x
The metabolism of 17 alpha‐ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.
Purba, H. S., Maggs, J. L., Orme, M. L., Back, D. J., & Park, B. K. (1987). The metabolism of 17 alpha‐ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.. British Journal of Clinical Pharmacology, 23(4), 447-453. doi:10.1111/j.1365-2125.1987.tb03074.x
The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form
Back, D. J., Killick, S. R., Stevenson, P. J., Shenoy, N., Elstein, M., & Cohen, M. (1987). The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. Contraception, 36(3), 321-326. doi:10.1016/0010-7824(87)90102-8
Tolbutamide 4‐hydroxylase activity of human liver microsomes: effect of inhibitors.
Purba, H. S., Back, D. J., & Orme, M. L. (1987). Tolbutamide 4‐hydroxylase activity of human liver microsomes: effect of inhibitors.. British Journal of Clinical Pharmacology, 24(2), 230-234. doi:10.1111/j.1365-2125.1987.tb03167.x
1986
Use of Oral Contraceptives by Women With Epilepsy
Orme, M. (1986). Use of Oral Contraceptives by Women With Epilepsy. JAMA: The Journal of the American Medical Association, 256(21), 2962. doi:10.1001/jama.1986.03380210057019
Drug interactions between oral contraceptive steroids and antibiotics
Orme, M. L., & Back, D. J. (1986). Drug interactions between oral contraceptive steroids and antibiotics. British Dental Journal, 160(5), 169-170. doi:10.1038/sj.bdj.4805798
Contraceptive steroid concentrations in women with early active schistosomiasis: Lack of effect of antischistosomal drugs
El-Raghy, I., Back, D. J., Osman, F., Orme, M. L., & Fathalla, M. (1986). Contraceptive steroid concentrations in women with early active schistosomiasis: Lack of effect of antischistosomal drugs. Contraception, 33(4), 373-377. doi:10.1016/0010-7824(86)90099-5
Inhibition of estrogen 2-hydroxylase
Purba, H. S., Back, D. J., & Breckenridge, A. M. (1986). Inhibition of estrogen 2-hydroxylase. Journal of Steroid Biochemistry, 24(5), 1091-1093. doi:10.1016/0022-4731(86)90365-1
Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro
Riviere, J. H., & Back, D. J. (1986). Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro. Chemico-Biological Interactions, 59, 301-308. doi:10.1016/s0009-2797(86)80075-8
Interactions between oral contraceptive steroids and broad-spectrum antibiotics
ORME, M. L., & BACK, D. J. (1986). Interactions between oral contraceptive steroids and broad-spectrum antibiotics. Clinical and Experimental Dermatology, 11(4), 327-331. doi:10.1111/j.1365-2230.1986.tb00471.x
Intestinal absorption of oestrone, oestrone glucuronide and oestrone sulphate in the rat in situ—II. Studies with the Doluisio technique
SI Mui Sim., & Back, D. J. (1986). Intestinal absorption of oestrone, oestrone glucuronide and oestrone sulphate in the rat in situ—II. Studies with the Doluisio technique. Journal of Steroid Biochemistry, 24(5), 1085-1089. doi:10.1016/0022-4731(86)90364-x
Pharmacokinetics of oral contraceptive steroids in Egyptian women: Studies with ovral, nordette and norminest
El-Raghy, I., Back, D. J., Makeram, M., Salem, H., Osman, F., Fathalla, M., & Orme, M. L. (1986). Pharmacokinetics of oral contraceptive steroids in Egyptian women: Studies with ovral, nordette and norminest. Contraception, 33(4), 379-384. doi:10.1016/0010-7824(86)90100-9
The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy
Grimmer, S. F. M., Back, D. J., Orme, M. L., Cowie, A., Gilmore, I., & Tjia, J. (1986). The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. Contraception, 33(1), 51-59. doi:10.1016/0010-7824(86)90032-6
The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids
Crawford, P., Chadwick, D., Cleland, P., Tjia, J., Cowie, A., Back, D. J., & L'E Orme, M. (1986). The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception, 33(1), 23-29. doi:10.1016/0010-7824(86)90028-4
1985
Effect of mefloquine on hepatic drug metabolism in the rat: Comparative study with primaquine
Riviere, J. H., & Back, D. J. (1985). Effect of mefloquine on hepatic drug metabolism in the rat: Comparative study with primaquine. Biochemical Pharmacology, 34(4), 567-571. doi:10.1016/0006-2952(85)90191-1
A non-chromatographic radioimmunoassay for 3-oxo desogestrel
Shaw, M. A., Back, D. J., Cowie, A. M., & Orme, M. C. L. (1985). A non-chromatographic radioimmunoassay for 3-oxo desogestrel. Journal of Steroid Biochemistry, 22(1), 111-113. doi:10.1016/0022-4731(85)90149-9
Inhibition of tolbutamide metabolism by substituted imidazole drugs <i>in vivo</i>: evidence for a structure‐activity relationship
Back, D. J., & Tjia, J. F. (1985). Inhibition of tolbutamide metabolism by substituted imidazole drugs <i>in vivo</i>: evidence for a structure‐activity relationship. British Journal of Pharmacology, 85(1), 121-126. doi:10.1111/j.1476-5381.1985.tb08838.x
Intestinal absorption of oestrone, oestrone glucuronide and oestrone sulphate in the rat in situ—I. Importance of hydrolytic enzymes on conjugate absorption
Si Mui Sim., & Back, D. J. (1985). Intestinal absorption of oestrone, oestrone glucuronide and oestrone sulphate in the rat in situ—I. Importance of hydrolytic enzymes on conjugate absorption. Journal of Steroid Biochemistry, 22(6), 781-788. doi:10.1016/0022-4731(85)90286-9
Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism.
Winstanley, P. A., Tjia, J., Back, D. J., Hobson, D., & Breckenridge, A. M. (1985). Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism.. British Journal of Clinical Pharmacology, 20(1), 47-53. doi:10.1111/j.1365-2125.1985.tb02797.x
Norethisterone concentration in breast milk and infant and maternal plasma during ethynodiol diacetate administration
Cooke, I. D., Back, D. J., & Shroff, N. E. (1985). Norethisterone concentration in breast milk and infant and maternal plasma during ethynodiol diacetate administration. Contraception, 31(6), 611-621. doi:10.1016/0010-7824(85)90061-7
The effect of some benzimidazoles on the disposition of antipyrine and tolbutamide from the rat isolated perfused liver
Ward, S. A., Mihaly, G. W., Tjia, J. F., & Back, D. J. (1985). The effect of some benzimidazoles on the disposition of antipyrine and tolbutamide from the rat isolated perfused liver. Journal of Pharmacy and Pharmacology, 37(1), 62-64. doi:10.1111/j.2042-7158.1985.tb04934.x
The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
el‐Raghy, I., Back, D. J., Osman, F., Nafeh, M. A., & Orme, M. L. (1985). The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.. British Journal of Clinical Pharmacology, 20(4), 313-316. doi:10.1111/j.1365-2125.1985.tb05069.x
The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
Riviere, J. H., Back, D. J., Breckenridge, A. M., & Howells, R. E. (1985). The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.. British Journal of Clinical Pharmacology, 20(5), 469-474. doi:10.1111/j.1365-2125.1985.tb05099.x
1984
ISOTRETINOIN AND CONTRACEPTION
Orme, M., Back, D. J., Shaw, M. A., Allen, W. L., Tjia, J., Cunliffe, W. J., & Jones, D. H. (1984). ISOTRETINOIN AND CONTRACEPTION. The Lancet, 324(8405), 752-753. doi:10.1016/s0140-6736(84)92659-x
An investigation of the effects of phenobarbitone on the pharmacokinetics of norethindrone in the rat using liver perfusion and everted gut sacs
Back, D. J., Macnee, C. M., Orme, M. L., Rowe, P. H., & Smith, E. (1984). An investigation of the effects of phenobarbitone on the pharmacokinetics of norethindrone in the rat using liver perfusion and everted gut sacs. Biochemical Pharmacology, 33(10), 1595-1600. doi:10.1016/0006-2952(84)90279-x
PHARMACOKINETICS AND "POTENCY" OF CONTRACEPTIVE STEROIDS
Back, D. J., Breckenridge, A., Orme, M., & Shaw, M. A. (1984). PHARMACOKINETICS AND "POTENCY" OF CONTRACEPTIVE STEROIDS. The Lancet, 323(8369), 171. doi:10.1016/s0140-6736(84)90113-2
2‐Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.
Back, D. J., Maggs, J. L., Purba, H. S., Newby, S., & Park, B. K. (1984). 2‐Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.. British Journal of Clinical Pharmacology, 18(4), 603-607. doi:10.1111/j.1365-2125.1984.tb02511.x
Distribution of estrone sulfatase activity in the intestine of germfree and conventional rats
Huijghebaert, S. M., Si Mui Sim., Back, D. J., & Eyssen, H. J. (1984). Distribution of estrone sulfatase activity in the intestine of germfree and conventional rats. Journal of Steroid Biochemistry, 20(5), 1175-1179. doi:10.1016/0022-4731(84)90363-7
Drug metabolism and tropical disease
BRECKENRIDGE, A., AWADZI, K., BACK, D. J., EDWARDS, G., GILLES, H., ORME, M., & WARD, S. (1984). Drug metabolism and tropical disease. Biochemical Society Transactions, 12(1), 90-95. doi:10.1042/bst0120090
Inhibition of hepatic microsomal enzymes by gossypol in the rat
Xiao-Nian, M., & Back, D. J. (1984). Inhibition of hepatic microsomal enzymes by gossypol in the rat. Contraception, 30(1), 89-97. doi:10.1016/0010-7824(84)90082-9
Interindividual variability in oral contraceptive disposition
Back, D. J., & Orme, M. L. (1984). Interindividual variability in oral contraceptive disposition. Trends in Pharmacological Sciences, 5, 480-483. doi:10.1016/0165-6147(84)90514-5
Overestimation of low progesterone concentrations by a commercial radioimmunoassay kit.
Allen, W. L., Back, D. J., & Shaw, M. A. (1984). Overestimation of low progesterone concentrations by a commercial radioimmunoassay kit.. Clinical Chemistry, 30(3), 495-496. doi:10.1093/clinchem/30.3.495a
Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine
Back, D. J., Breckenridge, A. M., Grimmer, S. F. M., Orme, M. L., & Purba, H. S. (1984). Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine. Contraception, 30(3), 289-295. doi:10.1016/0010-7824(84)90092-1
Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat
Back, D. J., Sutcliffe, F., & Tjia, J. F. (1984). Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat. British Journal of Pharmacology, 81(3), 557-562. doi:10.1111/j.1476-5381.1984.tb10109.x
1983
Drug interactions with oral contraceptive steroids.
Back, D. J., Breckenridge, A. M., & Orme, M. L. (1983). Drug interactions with oral contraceptive steroids.. IPPF Medical Bulletin, 17(1), 1-2.
Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat
Back, D. J., Purba, H. S., Staiger, C., Orme, M. L., & Breckenridge, A. M. (1983). Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochemical Pharmacology, 32(2), 257-263. doi:10.1016/0006-2952(83)90553-1
Adsorption of pregnanediol-3α-glucuronide by plastics and glass
Shaw, M. A., & Back, D. J. (1983). Adsorption of pregnanediol-3α-glucuronide by plastics and glass. Journal of Steroid Biochemistry, 19(5), 1681-1682. doi:10.1016/0022-4731(83)90391-6
Clinical Pharmacokinetics of Oral Contraceptive Steroids
Orme, M. L., Back, D. J., & Breckenridge, A. M. (1983). Clinical Pharmacokinetics of Oral Contraceptive Steroids. Clinical Pharmacokinetics, 8(2), 95-136. doi:10.2165/00003088-198308020-00001
Effect of chloroquine and primaquine on antipyrine metabolism.
Back, D. J., Purba, H. S., Park, B. K., Ward, S. A., & Orme, M. L. (1983). Effect of chloroquine and primaquine on antipyrine metabolism.. British Journal of Clinical Pharmacology, 16(5), 497-502. doi:10.1111/j.1365-2125.1983.tb02206.x
Gastrointestinal absorption of estrone sulfate in germfree and conventional rats
Si Mui Sim., Huijghebaert, S., Back, D. J., & Eyssen, H. J. (1983). Gastrointestinal absorption of estrone sulfate in germfree and conventional rats. Journal of Steroid Biochemistry, 18(4), 499-503. doi:10.1016/0022-4731(83)90071-7
Oral contraceptives and ascorbic acid metabolism
Back, D. J., & Orme, M. (1983). Oral contraceptives and ascorbic acid metabolism. The American Journal of Clinical Nutrition, 37(2), 330. doi:10.1093/ajcn/37.2.330
Potential problems with aqueous steroid solutions
Sim, S. M., Back, D. J., & Tjia, J. F. (1983). Potential problems with aqueous steroid solutions. Journal of Pharmacy and Pharmacology, 35(3), 200. doi:10.1111/j.2042-7158.1983.tb04312.x
Potential problems with aqueous steroid solutions.
Sim, S. M., Back, D. J., & Tjia, J. F. (1983). Potential problems with aqueous steroid solutions.. The Journal of pharmacy and pharmacology, 35(3), 200. doi:10.1111/j.2042-7158.1983.tb04312.x
Sulphaphenazole and drug oxidation in man.
Back, D. B., Park, B. K., Tjia, J. F., & Newby, S. N. (1983). Sulphaphenazole and drug oxidation in man.. British Journal of Clinical Pharmacology, 16(4), 460-461. doi:10.1111/j.1365-2125.1983.tb02199.x
The effect of cotrimoxazole on oral contraceptive steroids in women
Grimmer, S. F. M., Allen, W. L., Back, D. J., Breckenridge, A. M., Orme, M., & Tjia, J. (1983). The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception, 28(1), 53-59. doi:10.1016/s0010-7824(83)80005-5
Urinary concentrations of steroid glucuronides in women taking oral contraceptives
Shaw, M. A., Back, D. J., Aird, S. A., Grimmer, S. F. M., & Orme, M. C. L. (1983). Urinary concentrations of steroid glucuronides in women taking oral contraceptives. Contraception, 28(1), 69-75. doi:10.1016/s0010-7824(83)80007-9
1982
An antibiotic interaction with ethinyloestradiol in the rat and rabbit
Back, D. J., Breckenridge, A. M., Cross, K. J., Orme, M. L., & Thomas, E. (1982). An antibiotic interaction with ethinyloestradiol in the rat and rabbit. Journal of Steroid Biochemistry, 16(3), 407-413. doi:10.1016/0022-4731(82)90053-x
INTERACTION BETWEEN ETHINYLESTRADIOL AND ASCORBIC-ACID
BACK, D. J., BRECKENRIDGE, A. M., MACIVER, M., ORME, M. L., PURBA, H., & ROWE, P. H. (1982). INTERACTION BETWEEN ETHINYLESTRADIOL AND ASCORBIC-ACID. CONTRACEPTION FERTILITE SEXUALITE, 10(9), 547-549. Retrieved from https://www.webofscience.com/
Oral contraceptive steroid plasma concentrations in smokers and non-smokers (author's transl).
Crawford, F. E., Back, D. J., Orme, M. L., & Breckenridge, A. M. (1982). Oral contraceptive steroid plasma concentrations in smokers and non-smokers (author's transl).. Gynécologie Obstétrique Fertilité & Sénologie, 10(3), 143-148.
The effects of ampicillin oral contraceptive steroids in women.
Back, D. J., Breckenridge, A. M., MacIver, M., Orme, M., Rowe, P. H., Staiger, C., . . . Tjia, J. (1982). The effects of ampicillin oral contraceptive steroids in women.. British Journal of Clinical Pharmacology, 14(1), 43-48. doi:10.1111/j.1365-2125.1982.tb04932.x
The enzyme inducing effect of rifampicin in the rhesus monkey and its lack of interaction with oral contraceptive steroids
Back, D. J., Barkfeldt, J. O., Breckenridge, A. M., Odlind, V., Orme, M., Park, B. K., . . . Victor, A. (1982). The enzyme inducing effect of rifampicin in the rhesus monkey and its lack of interaction with oral contraceptive steroids. Contraception, 25(3), 307-316. doi:10.1016/0010-7824(82)90054-3
The gut wall metabolism of ethinyloestradiol and its contribution to the pre‐systemic metabolism of ethinyloestradiol in humans.
Back, D. J., Breckenridge, A. M., MacIver, M., Orme, M., Purba, H. S., Rowe, P. H., & Taylor, I. (1982). The gut wall metabolism of ethinyloestradiol and its contribution to the pre‐systemic metabolism of ethinyloestradiol in humans.. British Journal of Clinical Pharmacology, 13(3), 325-330. doi:10.1111/j.1365-2125.1982.tb01382.x
1981
Interaction of ethinyloestradiol with ascorbic acid
Back, D. J., Breckenridge, A. M., & Orme, M. L. (1981). Interaction of ethinyloestradiol with ascorbic acid. BMJ, 282(6281), 2057. doi:10.1136/bmj.282.6281.2057-a
Oral contraceptive steroid plasma concentrations in smokers and non-smokers.
Crawford, F. E., Back, D. J., Orme, M. L., & Breckenridge, A. M. (1981). Oral contraceptive steroid plasma concentrations in smokers and non-smokers.. BMJ, 282(6279), 1829-1830. doi:10.1136/bmj.282.6279.1829
Interaction of ethinyloestradiol with ascorbic acid in man.
Back, D. J., Breckenridge, A. M., MacIver, M., Orme, M. L., Purba, H., & Rowe, P. H. (1981). Interaction of ethinyloestradiol with ascorbic acid in man.. BMJ, 282(6275), 1516. doi:10.1136/bmj.282.6275.1516
Absorption of oestrone sulphate from the gastrointestinal tract of the rat
Back, D. J., Chapman, C. R., May, S. A., & Rowe, P. H. (1981). Absorption of oestrone sulphate from the gastrointestinal tract of the rat. Journal of Steroid Biochemistry, 14(4), 347-356. doi:10.1016/0022-4731(81)90153-9
INTESTINAL-ABSORPTION OF ESTRONE SULFATE IN THE RAT
BACK, D. J., BRECKENRIDGE, A. M., CHAPMAN, C. R., CRAWFORD, F. E., ORME, M. L., & ROWE, P. H. (1981). INTESTINAL-ABSORPTION OF ESTRONE SULFATE IN THE RAT. BRITISH JOURNAL OF PHARMACOLOGY, 72(3), P541. Retrieved from https://www.webofscience.com/
Interindividual Variation and Drug Interactions with Hormonal Steroid Contraceptives
Back, D. J., Breckenridge, A. M., Crawford, F. E., Maclver, M., Orme, M. L., & Rowe, P. H. (1981). Interindividual Variation and Drug Interactions with Hormonal Steroid Contraceptives. Drugs, 21(1), 46-61. doi:10.2165/00003495-198121010-00003
METABOLISM OF NORETHISTERONE OENANTHATE INVITRO
BACK, D. J., BRECKENRIDGE, A. M., CHAPMAN, C. R., CRAWFORD, F. E., ORME, M. L., & ROWE, P. H. (1981). METABOLISM OF NORETHISTERONE OENANTHATE INVITRO. BRITISH JOURNAL OF PHARMACOLOGY, 72(3), P538. Retrieved from https://www.webofscience.com/
Studies on the enzymatic cleavage of norethisterone oenanthate
Back, D. J., Breckenridge, A. M., Chapman, C. R., Crawford, F. E., Olsen, K. A., Orme, M. L., & Rowe, P. H. (1981). Studies on the enzymatic cleavage of norethisterone oenanthate. Contraception, 23(2), 125-132. doi:10.1016/0010-7824(81)90098-6
THE EFFECT OF CIGARETTE-SMOKING ON PLASMA-CONCENTRATIONS OF ORAL-CONTRACEPTIVE STEROIDS
CRAWFORD, F. E., BACK, D. J., ORME, M. L., & BRECKENRIDGE, A. M. (1981). THE EFFECT OF CIGARETTE-SMOKING ON PLASMA-CONCENTRATIONS OF ORAL-CONTRACEPTIVE STEROIDS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 11(4), P438-P439. Retrieved from https://www.webofscience.com/
The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa.
Back, D. J., Bates, M., Breckenridge, A. M., Ellis, A., Hall, J. M., Maciver, M., . . . Rowe, P. H. (1981). The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa.. British Journal of Clinical Pharmacology, 11(3), 275-278. doi:10.1111/j.1365-2125.1981.tb00534.x
The pharmacokinetics of levonorgestrel and ethynylestradiol in women — Studies with ovran and ovranette
Back, D. J., Bates, M., Breckenridge, A. M., Hall, J. M., MacIver, M., Orme, M. L., . . . Rowe, P. H. (1981). The pharmacokinetics of levonorgestrel and ethynylestradiol in women — Studies with ovran and ovranette. Contraception, 23(3), 229-239. doi:10.1016/0010-7824(81)90045-7
The pharmacokinetics of oestrone sulphate in the rat
Back, D. J., Breckenridge, A. M., Crawford, F. E., Giles, M., Orme, M. L. E., & Rowe, P. H. (1981). The pharmacokinetics of oestrone sulphate in the rat. Journal of Steroid Biochemistry, 14(10), 1045-1047. doi:10.1016/0022-4731(81)90214-4
1980
Influence of environmental chemicals on drug therapy in humans: studies with contraceptive steroids.
Breckenridge, A. M., Back, D. J., Cross, K., Crawford, F., MacIver, M., Orme, M. L., . . . Smith, E. (1980). Influence of environmental chemicals on drug therapy in humans: studies with contraceptive steroids.. Ciba Foundation symposium, 76, 289-306. doi:10.1002/9780470720592.ch16
The interaction of antibiotics with ethinyloestradiol in the rat and rabbit [proceedings].
Back, D. J., Breckenridge, A. M., Crawford, F. E., Cross, K. J., Orme, M. L., & Rowe, P. H. (1980). The interaction of antibiotics with ethinyloestradiol in the rat and rabbit [proceedings].. British Journal of Pharmacology, 68(1), 118p.
Clinical pharmacology of oral contraceptive steroids: drug interactions
Back, D. J., Breckenridge, A. M., Orme, M., & Rowe, P. H. (1980). Clinical pharmacology of oral contraceptive steroids: drug interactions. Journal of Obstetrics and Gynaecology, 1(2), 126-138. doi:10.3109/01443618009067363
PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS IN THE RABBIT AND RAT
BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., ORME, M. L., & ROWE, P. H. (1980). PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS IN THE RABBIT AND RAT. British Journal of Pharmacology, 69(3), 441-452. doi:10.1111/j.1476-5381.1980.tb07033.x
Reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat: Correlation with changes in the gut flora
Back, D. J., Breckenridge, A. M., Crawford, F. E., Cross, K. J., Orme, M. L., Percival, A., & Rowe, P. H. (1980). Reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat: Correlation with changes in the gut flora. Journal of Steroid Biochemistry, 13(1), 95-100. doi:10.1016/0022-4731(80)90118-1
The effect of oral contraceptive steroids and enzyme inducing drugs on sex hormone binding globulin capacity in women [proceedings]
Back, D. J., Breckenridge, A. M., Crawford, F. E., MacIver, M., Orme, M. L., Perucca, E., . . . Smith, E. (1980). The effect of oral contraceptive steroids and enzyme inducing drugs on sex hormone binding globulin capacity in women [proceedings]. British Journal of Clinical Pharmacology, 9(1). doi:10.1111/j.1365-2125.1980.tb04817.x
The effect of rifampicin oh the pharmacokinetics of ethynylestradiol in women
Back, D. J., Breckenridge, A. M., Crawford, F. E., Hall, J. M., MacIver, M., Orme, M. L., . . . Watts, M. J. (1980). The effect of rifampicin oh the pharmacokinetics of ethynylestradiol in women. Contraception, 21(2), 135-143. doi:10.1016/0010-7824(80)90125-0
The in vitro metabolism of ethinyloestradiol, levonorgestrel and mestranol by human jejunal mucosa [proceedings]
Back, D. J., Bates, M., Breckenridge, A. M., Crawford, F. E., Ellis, A., Hall, J. M., . . . Rowe, P. H. (1980). The in vitro metabolism of ethinyloestradiol, levonorgestrel and mestranol by human jejunal mucosa [proceedings]. In British Journal of Clinical Pharmacology Vol. 9. Wiley. doi:10.1111/j.1365-2125.1980.tb04841.x
The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy
Back, D. J., Bates, M., Bowden, A., Breckenridge, A. M., Hall, M. J., Jones, H., . . . Smith, E. (1980). The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception, 22(5), 495-503. doi:10.1016/0010-7824(80)90102-x
The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women
Back, D. J., Bolt, H. M., Breckenridge, A. M., Crawford, F. E., Orme, M. L., Rowe, P. H., & Schindler, A. E. (1980). The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. Contraception, 21(2), 145-153. doi:10.1016/0010-7824(80)90126-2
1979
The pharmacokinetics of ethinyloestradiol in women [proceedings].
Back, D. J., Bolt, H. M., Breckenridge, A. M., Crawford, F. E., MacIver, M., Orme, M. L., . . . Smith, E. (1979). The pharmacokinetics of ethinyloestradiol in women [proceedings].. British Journal of Pharmacology, 66(3), 441p-442p.
The effect of rifampicin on norethisterone pharmacokinetics
Back, D. J., Breckenridge, A. M., Crawford, F., MacIver, M., Orme, M., Park, B. K., . . . Smith, E. (1979). The effect of rifampicin on norethisterone pharmacokinetics. European Journal of Clinical Pharmacology, 15(3), 193-197. doi:10.1007/bf00563105
The effect of rifampicin on liver blood flow, microsomal enzyme activity and bile flow in the rat
Back, D. J., Cross, K. J., Hiley, C. R., & Yates, M. S. (1979). The effect of rifampicin on liver blood flow, microsomal enzyme activity and bile flow in the rat. Biochemical Pharmacology, 28(8), 1293-1296. doi:10.1016/0006-2952(79)90427-1
Therapy with oral contraceptive steroids and antibiotics
ORME, M. L., & BACK, D. J. (1979). Therapy with oral contraceptive steroids and antibiotics. Journal of Antimicrobial Chemotherapy, 5(2), 124-126. doi:10.1093/jac/5.2.124
Effects of phenobarbitone on hepatic microsomal enzyme activity and liver blood flow in spontaneously hypertensive rats
Yates, M. S., Hiley, C. R., & Back, D. J. (1979). Effects of phenobarbitone on hepatic microsomal enzyme activity and liver blood flow in spontaneously hypertensive rats. Life Sciences, 24(6), 535-540. doi:10.1016/0024-3205(79)90175-9
An investigation of the pharmacokinetics of ethynylestsadiol in women using badioimmunoassay
Back, D. J., Breckenridge, A. M., Crawford, F. E., MacIver, M., Orme, M. L., Rowe, P. H., & Watts, M. J. (1979). An investigation of the pharmacokinetics of ethynylestsadiol in women using badioimmunoassay. Contraception, 20(3), 263-273. doi:10.1016/0010-7824(79)90098-2
Interaction between oral contraceptives and other drugs
Breckenridge, A. M., Back, D. J., & Orme, M. (1979). Interaction between oral contraceptives and other drugs. Pharmacology & Therapeutics, 7(3), 617-626. doi:10.1016/0163-7258(79)90044-5
Plasma Xa inhibitory activities and plasma concentrations of norgestrel and ethinyloestradiol in women on oral contraceptive steroids.
Back, D. J., Bates, M., Burke, M. W., Breckenridge, A. M., Crawford, F. E., MacIver, M., . . . Webster, S. (1979). Plasma Xa inhibitory activities and plasma concentrations of norgestrel and ethinyloestradiol in women on oral contraceptive steroids.. British Journal of Clinical Pharmacology, 8(5), 505-506. doi:10.1111/j.1365-2125.1979.tb01034.x
1978
Drug interactions with oral contraceptives
Drug interactions with oral contraceptives (1987). Reactions, 166(1), 3. doi:10.1007/bf03270765
First-pass effect of norethindrone in rabbits and rats.
Back, D. J., Breckenridge, A. M., Crawford, F. E., Orme, M. L., Rowe, P. H., & Smith, E. (1978). First-pass effect of norethindrone in rabbits and rats.. The Journal of Pharmacology and Experimental Therapeutics, 207(2), 555-565. doi:10.1016/s0022-3565(25)31453-9
The reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat [proceedings].
Back, D. J., Breckenridge, A. M., Cross, K. J., Orme, M. L., Percival, A., & Rowe, P. H. (1978). The reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat [proceedings].. British Journal of Pharmacology, 64(3), 401p.
Biliary excretion of synthetic sex steroids in heterozygous and homozygous gunn rats
Back, D. J., Breckenridge, A. M., Crawford, F. E., Cross, K. J., Orme, M. L., Rowe, P. H., . . . Todd, K. (1978). Biliary excretion of synthetic sex steroids in heterozygous and homozygous gunn rats. Life Sciences, 23(10), 1053-1056. doi:10.1016/0024-3205(78)90666-5
The effect of urethane and pentobarbital anaesthesia and hepatic portal vein catheterization on liver blood flow in the rat
Hiley, C. R., Yates, M. S., & Back, D. J. (1978). The effect of urethane and pentobarbital anaesthesia and hepatic portal vein catheterization on liver blood flow in the rat. Experientia, 34(8), 1061-1062. doi:10.1007/bf01915348
The interaction of antibiotics with synthetic steroids in the rat [proceedings].
Back, D. J., Breckenridge, A. M., Challiner, M., Crawford, F. E., Orme, M. L., Rowe, P. H., & Smith, E. (1978). The interaction of antibiotics with synthetic steroids in the rat [proceedings].. British Journal of Pharmacology, 62(3), 441p.
242. Plasma ethinyloestradiol concentration in rabbits and women
Back, D. J., Breckenridge, A. M., Crawford, F. E., Orme, M. L., Rowe, P. H., Sloan, T. P., & Smith, E. (1978). 242. Plasma ethinyloestradiol concentration in rabbits and women. Journal of Steroid Biochemistry, 9(9), 863. doi:10.1016/0022-4731(78)90942-1
51. The metabolism of norethisterone and ethinyloestradiol by rat gut wall
Back, D. J., Bates, M. W., Breckenridue, A. M., Crawford, F. E., Orme, M. L., Rowe, P. H., . . . Smith, E. (1978). 51. The metabolism of norethisterone and ethinyloestradiol by rat gut wall. Journal of Steroid Biochemistry, 9(9), 823. doi:10.1016/0022-4731(78)90751-3
Differential effects of hepatic microsomal enzyme inducing agents on liver blood flow
Yates, M. S., Hiley, C. R., Roberts, P. J., Back, D. J., & Crawford, F. E. (1978). Differential effects of hepatic microsomal enzyme inducing agents on liver blood flow. Biochemical Pharmacology, 27(22), 2617-2621. doi:10.1016/0006-2952(78)90336-2
Ethynylestradiol and norethindrone metabolism by everted sacs of rat ileum
Back, D. J., Bates, M. W., Breckenridge, A. M., Crawford, F. E., Orme, M. L., Rowe, P. H., . . . Smith, E. (1978). Ethynylestradiol and norethindrone metabolism by everted sacs of rat ileum. Contraception, 18(2), 127-135. doi:10.1016/0010-7824(78)90088-4
Kinetics of norethindrone in women; I. Radioimmunoassay and concentrations during multiple dosing
Back, D. J., Breckenridge, A. M., Crawford, F. E., McIver, M., Orme, M. L., Park, B. K., . . . Smith, E. (1978). Kinetics of norethindrone in women; I. Radioimmunoassay and concentrations during multiple dosing. Clinical Pharmacology & Therapeutics, 24(4), 439-447. doi:10.1002/cpt1978244439
Kinetics of norethindrone in women; II. Single‐dose kinetics
Back, D. J., Breckenridge, A. M., Crawford, F. E., McIver, M., Orme, M. L., Rowe, P. H., & Smith, E. (1978). Kinetics of norethindrone in women; II. Single‐dose kinetics. Clinical Pharmacology & Therapeutics, 24(4), 448-453. doi:10.1002/cpt1978244448
The effect of antibiotics on the enterohepatic circulation of ethinylestradiol and norethisterone in the rat
Back, D. J., Breckenridge, A. M., Challiner, M., Crawford, F. E., Orme, M. L., Rowe, P. H., & Smith, E. (1978). The effect of antibiotics on the enterohepatic circulation of ethinylestradiol and norethisterone in the rat. Journal of Steroid Biochemistry, 9(6), 527-531. doi:10.1016/0022-4731(78)90118-8
The pharmacokinetics of tritiated ethinylestradiol in the rabbit
Back, D. (1978). The pharmacokinetics of tritiated ethinylestradiol in the rabbit. Steroids, 32(4), 423-433. doi:10.1016/0039-128x(78)90056-9
1977
The pharmacokinetics of norethisterone in the rabbit and rat after systemic and oral administration: effect of phenobarbitone [proceedings].
Back, D. J., Breckenridge, A. M., Gay, F. E., Orme ML'E., Rowe, P. H., & Smith, E. (1977). The pharmacokinetics of norethisterone in the rabbit and rat after systemic and oral administration: effect of phenobarbitone [proceedings].. British Journal of Pharmacology, 60(2), 279p.
LSD: The distribution of [3H]LSD in the reproductive system of the male rat and placental transfer in the female rat
Back, D. J., & Singh, J. K. G. (1977). LSD: The distribution of [3H]LSD in the reproductive system of the male rat and placental transfer in the female rat. Experientia, 33(4), 501-502. doi:10.1007/bf01922236
Drug interactions with oral contraceptive steroids
Back, D. J., & L'E Orme, M. (1977). Drug interactions with oral contraceptive steroids. Prescribers Journal, 17(6), 137-142.
INFLUENCE OF .A. ROUTE OF ADMINISTRATION AND .B. PHENOBARBITONE ON PHARMACOKINETICS OF NORETHISTERONE IN RABBIT AND RAT
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., ORME, M. L., PARK, B. K., ROWE, P. H., & SMITH, E. (1977). INFLUENCE OF .A. ROUTE OF ADMINISTRATION AND .B. PHENOBARBITONE ON PHARMACOKINETICS OF NORETHISTERONE IN RABBIT AND RAT. ACTA ENDOCRINOLOGICA, 85, 67. Retrieved from https://www.webofscience.com/
PHARMACOKINETICS OF NORETHISTERONE DURING SINGLE AND MULTIPLE DOSING IN WOMEN AND CHANGES CAUSED BY RIFAMPICIN
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., ORME, M. L. E., PARK, B. K., ROWE, P. H., & SMITH, E. (1977). PHARMACOKINETICS OF NORETHISTERONE DURING SINGLE AND MULTIPLE DOSING IN WOMEN AND CHANGES CAUSED BY RIFAMPICIN. ACTA ENDOCRINOLOGICA, 85, 149. Retrieved from https://www.webofscience.com/
PHARMACOKINETICS OF NORETHISTERONE IN WOMEN
BACK, D. J., BRECKENRIDGE, A. M., GAY, F. E., MCIVER, M., ORME, M. L., PARK, B. K., . . . SMITH, E. (1977). PHARMACOKINETICS OF NORETHISTERONE IN WOMEN. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 4(6), P729-P730. Retrieved from https://www.webofscience.com/
Some effects of cyproterone and cyproterone acetate on the reproductive physiology of the male rat
Back, D. J., Glover, T. D., Shenton, J. C., & Boyd, G. P. (1977). Some effects of cyproterone and cyproterone acetate on the reproductive physiology of the male rat. Reproduction, 49(2), 237-243. doi:10.1530/jrf.0.0490237
1976
The biliary excretion of [3H] lysergic acid diethylamide in Wistar and gunn rats
Back, D. J., & Singh, J. K. G. (1976). The biliary excretion of [3H] lysergic acid diethylamide in Wistar and gunn rats. Experientia, 32(5), 616-617. doi:10.1007/bf01990195
Release of microquantities of cyproterone acetate from subcutaneous silastic capsules: Failure to produce an antifertility effect
Back, D. J., & Shenton, J. C. (1976). Release of microquantities of cyproterone acetate from subcutaneous silastic capsules: Failure to produce an antifertility effect. Contraception, 14(1), 17-24. doi:10.1016/s0010-7824(76)80004-2
1975
THE EFFECTS OF α-CHLOROHYDRIN ON THE COMPOSITION OF RAT AND RABBIT EPIDIDYMAL PLASMA: A POSSIBLE EXPLANATION OF SPECIES DIFFERENCE
BACK, D. J., GLOVER, T. D., SHENTON, J. C., & BOYD, G. P. (1975). THE EFFECTS OF α-CHLOROHYDRIN ON THE COMPOSITION OF RAT AND RABBIT EPIDIDYMAL PLASMA: A POSSIBLE EXPLANATION OF SPECIES DIFFERENCE. Reproduction, 45(1), 117-128. doi:10.1530/jrf.0.0450117
A comparison of the composition of epididymal plasma from the cauda epididymidis of the rat, hamster and guinea-pig
Back, D. J., & Shenton, J. C. (1975). A comparison of the composition of epididymal plasma from the cauda epididymidis of the rat, hamster and guinea-pig. Experientia, 31(4), 464-465. doi:10.1007/bf02026381
The presence of metabolites of 3H-testosterone in the lumen of the cauda epididymidis of the rat
Back, D. J. (1975). The presence of metabolites of 3H-testosterone in the lumen of the cauda epididymidis of the rat. Steroids, 25(3), 413-420. doi:10.1016/0039-128x(75)90097-5
1974
THE COMPOSITION OF EPIDIDYMAL PLASMA FROM THE CAUDA EPIDIDYMIDIS OF THE RAT
BACK, D. J., SHENTON, J. C., & GLOVER, T. D. (1974). THE COMPOSITION OF EPIDIDYMAL PLASMA FROM THE CAUDA EPIDIDYMIDIS OF THE RAT. Reproduction, 40(1), 211-214. doi:10.1530/jrf.0.0400211
THE PHARMACOKINETICS OF [<sup>14</sup>C]‐EDROPHONIUM IN NORMAL WISTAR RATS AND HOMOZYGOUS GUNN RATS WITH LIGATED RENAL PEDICLES
BACK, D. J., & CALVEY, T. N. (1974). THE PHARMACOKINETICS OF [<sup>14</sup>C]‐EDROPHONIUM IN NORMAL WISTAR RATS AND HOMOZYGOUS GUNN RATS WITH LIGATED RENAL PEDICLES. British Journal of Pharmacology, 51(1), 61-65. doi:10.1111/j.1476-5381.1974.tb09632.x
1973
Biliary excretion of 14 C-edrophonium and its glucuronide metabolite in Gunn rats.
Calvey, T. N., & Back, D. J. (1973). Biliary excretion of 14 C-edrophonium and its glucuronide metabolite in Gunn rats.. Arch Int Pharmacodyn, 201(1), 147-153.
Proceedings: The passage of (3H) testosterone into the cauda epididymidis of the rat
Back, D. (1973). Proceedings: The passage of (3H) testosterone into the cauda epididymidis of the rat. Reproduction, 35(3), 586-587. doi:10.1530/jrf.0.0350586
1972
The influence of secretin on the elimination of14C-Edrophonium in bile
Back, D. J., & Calvey, T. N. (1972). The influence of secretin on the elimination of14C-Edrophonium in bile. Experientia, 28(11), 1332-1334. doi:10.1007/bf01965328
Excretion of <sup>14</sup>C‐edrophonium and its metabolites in bile: role of the liver cell and the peribiliary vascular plexus
BACK, D. J., & CALVEY, T. N. (1972). Excretion of <sup>14</sup>C‐edrophonium and its metabolites in bile: role of the liver cell and the peribiliary vascular plexus. British Journal of Pharmacology, 44(3), 534-543. doi:10.1111/j.1476-5381.1972.tb07290.x
The removal of<sup>14</sup>C‐edrophonium from the circulation
Back, D. J., & Calvey, T. N. (1972). The removal of<sup>14</sup>C‐edrophonium from the circulation. British Journal of Pharmacology, 46(2), 355-357. doi:10.1111/j.1476-5381.1972.tb06882.x
1971
Infusion of secretin into the hepatic arterial circulation of the rat.
Back, D. J., & Calvey, T. N. (1971). Infusion of secretin into the hepatic arterial circulation of the rat.. The Journal of Physiology, 219(2), 14p.
The influence of secretion on the elimination of drugs in bile.
Back, D. J., & Calvey, T. N. (1971). The influence of secretion on the elimination of drugs in bile.. The Journal of Physiology, 219(2), 13p.
Biliary excretion of [14C]edrophonium and its glucuronide conjugate
Calvey, T. N., & Back, D. J. (1971). Biliary excretion of [14C]edrophonium and its glucuronide conjugate. Journal of Pharmacy and Pharmacology, 23(8), 642-643. doi:10.1111/j.2042-7158.1971.tb08738.x
The effect of bile pigments on the excretion of 14C-trimophonium glucuronide
Calvey, T. N., & Back, D. J. (1971). The effect of bile pigments on the excretion of 14C-trimophonium glucuronide. European Journal of Pharmacology, 13(2), 262-265. doi:10.1016/0014-2999(71)90159-2
The effect of organic anions on the biliary excretion of tri[14C]methyl-(3-hydroxyphenyl) ammonium <i>O</i>-glucuronide
Calvey, T. N., & Back, D. J. (1971). The effect of organic anions on the biliary excretion of tri[14C]methyl-(3-hydroxyphenyl) ammonium <i>O</i>-glucuronide. Biochemical Journal, 121(3), 41P-42P. doi:10.1042/bj1210041pb